RADIATION CONTROL - USE OF RADIONUCLIDES IN THE HEALING ARTS

ColoradoRegulations

Ask Donna

How this section applies to your facts.

Code of Colorado Regulations › 1000 Department of Public Health and Environment › 1007 Hazardous Materials and Waste Management Division › 6 CCR 1007-1 Part 07

This text was captured on Sep 30, 2026. It is a snapshot, not a live feed, so check the official code before relying on it.

Text

_________________________________________________________________________

Adopted by the Board of Health October 19, 2022, effective date December 15, 2022.

PART 7: USE OF RADIONUCLIDES IN THE HEALING ARTS

USE OF RADIONUCLIDES IN THE HEALING ARTS

Section A – General Information

7.1

Purpose and scope.

7.1.1

Authority

Rules and regulations set forth herein are adopted pursuant to the provisions of sections 25-1-

108, 25-1.5-101(1)(l), and 25-11-104, CRS.

7.1.2

Basis and Purpose.

A statement of basis and purpose accompanies this part and changes to this part. A copy may be

obtained from the Department.

7.1.3

Scope.

This part establishes requirements and provisions for the production, preparation, compounding

and use of radionuclides in the healing arts and for issuance of licenses authorizing the medical

use of this material. These requirements and provisions provide for the protection of the public

health and radiation safety of workers, the general public, patients, and human research subjects.

The requirements and provisions of this part are in addition to, and not in substitution for, others

in these regulations.

7.1.4

Applicability.

The requirements and provisions of these regulations apply to applicants and licensees subject to

this part unless specifically exempted.

7.1.5

Published material incorporated by reference.

7.1.5.1 Throughout this Part 7, federal regulations, state regulations, and standards or guidelines

of outside organizations have been adopted and incorporated by reference. Unless a

prior version of the incorporated material is otherwise specifically indicated, the materials

incorporated by reference cited herein include only those versions that were in effect as

of the most recent effective date of this Part 7 (December 15, 2022), and not later

amendments or editions of the incorporated material.

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

2

7.1.5.2 Materials incorporated by reference are available for public inspection, and copies

(including certified copies) can be obtained at reasonable cost, during normal business

hours from the Colorado Department of Public Health and Environment, Hazardous

Materials and Waste Management Division, 4300 Cherry Creek Drive South, Denver,

Colorado 80246. Additionally, https://www.colorado.gov/cdphe/radregs identifies where

the incorporated federal and state regulations are available to the public on the internet at

no cost. A copy of the materials incorporated in this Part is available for public inspection

at the state publications depository and distribution center.

7.1.5.3 Availability from Source Agencies or Organizations.

(1)

All federal agency regulations incorporated by reference herein are available at

no cost in the online edition of the Code of Federal Regulations (CFR) hosted by

the U.S. Government Printing Office, online at www.govinfo.gov.

(2)

All state regulations incorporated by reference herein are available at no cost in

the online edition of the Code of Colorado Regulations (CCR) hosted by the

Colorado Secretary of State’s Office, online at

https://www.sos.state.co.us/CCR/RegisterHome.do.

(3)

Copies of the standards or guidelines of outside organizations are available

either at no cost or for purchase from the source organizations listed below.

a.

The Federal Policy for the Protection of Human Subjects: hhs.gov or

https://www.hhs.gov/ohrp/regulations-and-policy/regulations/common-

rule/index.html or

U.S. Department of Health & Human Services

200 Independence Avenue, S.W.

Washington, D.C.20201

Phone: 1-877-696-6775.

b.

NUREG-1556, Vol. 9: nrc.gov or https://www.nrc.gov/reading-rm/doc-

collections/nuregs/staff/sr1556/ or

U.S. Nuclear Regulatory Commission

Washington, DC 20555-0001

Phone: 1-800-368-5642.

7.2

Definitions.

As used in this part, these terms have the definitions set forth as follows:

“Address of use” means the building(s) identified on the license where radioactive material may

be produced, prepared, received, used or stored.

“Area of use” means a portion of an address of use that has been set aside for the purpose of

producing, preparing, receiving, using, or storing radioactive material.

“Associate Radiation Safety Officer” means, for the purposes of Part 7, an individual who:

(1)

Meets the requirements in Appendix 7A and 7.65; and

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

3

(2)

Is currently identified as an Associate Radiation Safety Officer for the types of

use of radioactive material for which the individual has been assigned duties and

tasks by the Radiation Safety Officer on:

a.

A specific medical use license issued by the Department, NRC or an

Agreement State;

b.

A medical use permit issued by an NRC master material licensee.

“Authorized medical physicist” (AMP) means an individual who meets the requirements of

Appendix 7B; or

(1)

Is identified as an authorized medical physicist or teletherapy physicist on:

a.

A specific medical use license issued by the Department, NRC, or

Agreement State;

b.

A medical use permit issued by an NRC master material licensee;

c.

A permit issued by an NRC or Agreement State broad scope medical

use licensee; or

d.

A permit issued by an NRC master material license broad scope medical

use permittee.

“Authorized nuclear pharmacist” (ANP) means a pharmacist who meets the requirements of

Appendix 7C; or

(1)

Is identified as an authorized nuclear pharmacist on:

a.

A specific license issued by the Department, NRC, or Agreement State

that authorizes medical use or the practice of nuclear pharmacy;

b.

A permit issued by an NRC master material licensee that authorizes

medical use or the practice of nuclear pharmacy;

c.

A permit issued by an NRC or Agreement State broad scope medical

use licensee that authorizes medical use or the practice of nuclear

pharmacy; or

d.

A permit issued by an NRC master material license broad scope medical

use permittee that authorizes medical use or the practice of nuclear

pharmacy; or

(2)

Is identified as an authorized nuclear pharmacist by a commercial nuclear

pharmacy that has been authorized to identify authorized nuclear pharmacists; or

(3)

Is designated as an authorized nuclear pharmacist in accordance with Part 3.

“Authorized user” (AU) means a physician, dentist, or podiatrist who meets the applicable

requirements of Appendix 7D through Appendix 7M; or

(1)

Is identified as an authorized user on:

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

4

a.

A Department, NRC, or Agreement State license that authorizes the

medical use of radioactive material;

b.

A permit issued by an NRC master material licensee that is authorized to

permit the medical use of radioactive material;

c.

A permit issued by an NRC or Agreement State specific licensee of

broad scope that is authorized to permit the medical use of radioactive

material; or

d.

A permit issued by an NRC master material license broad scope

permittee that is authorized to permit the medical use of radioactive

material.

“Brachytherapy” means a method of radiation therapy in which plated, embedded, activated, or

sealed sources are utilized to deliver a radiation dose at a distance of up to a few centimeters, by

surface, intracavitary, intraluminal or interstitial application.

“Brachytherapy source” means a radioactive source or a manufacturer-assembled source train or

a combination of these sources that is designed to deliver a therapeutic dose within a distance of

a few centimeters.

“Client” means, for mobile medical service, the person for whom, or in conjunction with whom,

medical service is provided.

“Client's address” means the address of use for the purpose of providing mobile medical service

in accordance with 7.27.

“Dedicated check source” means a radioactive source that is used to assure the consistent

response of a radiation detection or measurement device over several months or years.

“Dentist” means an individual licensed by a State or Territory of the United States, the District of

Columbia or the Commonwealth of Puerto Rico to practice dentistry.

“Diagnostic clinical procedures manual” means a collection of written procedures that describes

each method (and other instructions and precautions) by which the licensee performs diagnostic

clinical procedures; where each diagnostic clinical procedure has been approved by the

authorized user and includes the radiopharmaceutical, dosage, and route of administration, or in

the case of sealed sources for diagnosis, the procedure.

“HDR”, see high dose-rate remote afterloader.

“High dose-rate remote afterloader” (HDR) means a device that remotely delivers a dose rate in

excess of 12 gray (1200 rad) per hour at the treatment site.

“LDR”, see low dose-rate remote afterloader.

“Low dose-rate remote afterloader” (LDR) means a device that remotely delivers a dose rate of

less than or equal to 2 gray (200 rad) per hour at the treatment site (at the specified distance).

“Management” means the chief executive officer, or other individual having the authority to

manage, direct, or administer the licensee's activities, or such person's' delegate(s).

“Manual brachytherapy” means a type of therapy in which brachytherapy sources are manually

applied or inserted.

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

5

“MDR”, see medium dose-rate remote afterloader”.

“Medical institution” means an organization in which two or more medical disciplines are

practiced.

“Medical event” means an event that meets the criteria in 7.21.1 or 7.21.2.

“Medical use” means, for the purposes of Part 7, the intentional internal or external administration

of radioactive material or the radiation from radioactive material to patients or human research

subjects under the supervision of an authorized user.

“Medium dose-rate remote afterloader” (MDR) means a brachytherapy device that remotely

delivers a dose rate of greater than 2 gray (200 rads) per hour, but less than, or equal to 12 gray

(1200 rads) per hour at the point or surface where the dose is prescribed.

“Mobile medical service” means the transportation of radioactive material to, or its medical use at,

the client’s address and/or a temporary job site.

“Nuclear medicine technologist” (NMT) means an individual who meets the requirements of

Appendix 7N and who under the supervision of an authorized user prepares or administers

radioactive drugs to patients or human research subjects, or performs in vivo or in vitro

measurements for medical purposes.

“Nuclear medicine technology” means the science and art of in vivo and in vitro detection and

measurement of radioactivity and the administration of radioactive drugs to patients or human

research subjects for diagnostic and therapeutic purposes.

“Ophthalmic physicist” means an individual who:

(1)

Meets the requirements in 7.41.6.1(2) and 7.65; and

(2)

Is identified as an ophthalmic physicist on a:

a.

Specific medical use license issued by the Department, NRC or an

Agreement State;

b.

Permit issued by the Department, NRC or Agreement State broad scope

medical use licensee;

c.

Medical use permit issued by a NRC master material licensee; or

d.

Permit issued by a NRC master material license broad scope medical

use permittee.

“Output” means the exposure rate, dose rate, or a quantity related in a known manner to these

rates, from a brachytherapy source, or a teletherapy, remote afterloader, or gamma stereotactic

radiosurgery unit, for a specified set of exposure conditions.

“Patient intervention” means actions by the patient or human research subject, whether

intentional or unintentional, such as dislodging or removing treatment devices or prematurely

terminating the administration.

“PDR”, see pulsed dose-rate remote afterloader.

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

6

“Pharmacist” means an individual licensed by a State or Territory of the United States, the District

of Columbia or the Commonwealth of Puerto Rico to practice pharmacy. (See also Authorized

nuclear pharmacist)

“Physician” means an individual licensed by a State or Territory of the United States, the District

of Columbia or the Commonwealth of Puerto Rico to prescribe drugs in the practice of medicine.

“Podiatrist” means an individual licensed by a State or Territory of the United States, the District

of Columbia or the Commonwealth of Puerto Rico to practice podiatry.

“Preceptor” means an individual who provides, directs or verifies training and experience required

for an individual to become an authorized user, an authorized medical physicist, an authorized

nuclear pharmacist, a Radiation Safety Officer, an Associate Radiation Safety Officer (see

appendices 7A through 7M, and 7P).

“Prescribed dosage” means the specified activity or range of activity of a radioactive drug as

documented in:

(1)

A written directive as specified in 7.11; or

(2)

Accordance with the directions of the authorized user for procedures performed

pursuant to 7.30, 7.32, or 7.36.

“Prescribed dose” means:

(1)

For gamma stereotactic radiosurgery, the total dose as documented in the written

directive;

(2)

For teletherapy, the total dose and dose per fraction as documented in the

written directive;

(3)

For manual brachytherapy, either the total source strength and exposure time or

the total dose, as documented in the written directive; or

(4)

For remote brachytherapy afterloaders, the total dose and dose per fraction as

documented in the written directive.

“Pulsed dose-rate remote afterloader” (PDR) means a special type of remote afterloading device

that uses a single source capable of delivering dose rates (at the specified distance) in the “high

dose-rate” range, but:

(1)

Is approximately one-tenth of the activity of typical high dose-rate remote

afterloader sources; and

(2)

Is used to simulate the radiobiology of a low dose rate treatment by inserting the

source for a given fraction of each hour.

“Radiation safety officer” (RSO) means, for the purposes of Part 7, an individual who has

demonstrated sufficient knowledge to apply radiation protection regulations appropriately, who in

accord with 7.7 has been assigned such responsibility by the licensee, and who meets the

requirements in Appendix 7A; or

(1)

Is identified as a Radiation Safety Officer on:

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

7

a.

A specific medical use license issued by the Department, NRC, or

Agreement State; or

b.

A medical use permit issued by an NRC master material licensee.

“Radioactive drug” means any chemical compound containing radioactive material that may be

used on or administered to patients or human research subjects as an aid in the diagnosis,

treatment, or prevention of disease or other abnormal condition.

“Sealed source” means radioactive material that is permanently bonded or fixed in a capsule or

matrix designed to prevent release and dispersal of the radioactive material under the most

severe conditions which are likely to be encountered in normal use and handling.

“Sealed Source and Device Registry” means the national registry that contains all the registration

certificates, generated by both the Nuclear Regulatory Commission and the Agreement States,

that summarize the radiation safety information for the sealed sources and devices and describe

the licensing and use conditions approved for the product.

“Stereotactic radiosurgery” means the use of external radiation in conjunction with a stereotactic

guidance device to precisely deliver a dose to a treatment site.

“Structured educational program” means an accredited educational program designed to impart

particular knowledge and practical education through interrelated studies and supervised training.

“Teletherapy”, as used in this part, means a method of radiation therapy in which collimated

gamma rays are delivered at a distance from the patient or human research subject.

“Temporary job site”, as used in Part 7, means a location where mobile medical services are

confined to the mobile unit not at a licensed address of use.

“Therapeutic dosage” means a dosage of unsealed radioactive material that is intended to deliver

a radiation dose to a patient or human research subject for palliative or curative treatment.

“Therapeutic dose” means a radiation dose delivered from a sealed source containing radioactive

material to a patient or human research subject for palliative or curative treatment.

“Treatment site” means the anatomical description of the tissue intended to receive a radiation

dose, as described in a written directive.

“Trunnion” means a support bar sometimes used as a bearing instead of a socket.

“Type of use” means use of radioactive material as specified under 7.30, 7.32, 7.36, 7.40, 7.42,

7.48 or 7.62.

“Unit dosage” means a dosage that:

(1)

Is obtained or prepared in accordance with the regulations for uses described in

7.30, 7.32, or 7.36; and

(2)

Is to be administered as a single dosage to a patient or human research subject

without any further manipulation of the dosage after it is initially prepared.

“Written directive” means an authorized user's written order for the administration of radioactive

material or radiation from radioactive material to a specific patient or human research subject, as

specified in 7.11.

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

8

GENERAL REGULATORY REQUIREMENTS

7.3

License required.

7.3.1

7.3.1.1 A person may manufacture, produce, acquire, receive, possess, prepare, use, or transfer

radioactive material for medical use only in accordance with a specific license issued by

the Department, an Agreement State or NRC, or as allowed in 7.3.1.2.

7.3.1.2 A specific license is not needed for an individual who:

(1)

Receives, possess, uses, or transfers radioactive material in accordance with the

regulations under the supervision of an authorized user as provided in 7.10,

unless prohibited by license condition; or

(2)

Prepares unsealed radioactive material for medical use in accordance with the

regulations under the supervision of an authorized nuclear pharmacist or

authorized user as provided in 7.10, unless prohibited by license condition.

7.3.2

Provisions for the protection of Human Research Subjects.

A licensee may conduct research involving human subjects using radioactive material under the

following conditions:

7.3.2.1 For research conducted, funded, supported, or regulated by a federal agency which has

implemented The Federal Policy for the Protection of Human Subjects (Federal Policy),

the licensee shall:

(1)

Obtain prior informed consent from the human research subjects; and

(2)

Obtain prior review and approval of the research activities by an “Institutional

Review Board” in accordance with the meaning of these terms as defined and

described in the Federal Policy; or

7.3.2.2 For research not conducted, funded, supported, or regulated by a federal agency which

has implemented the Federal Policy, then:

(1)

The licensee shall apply for and receive a specific amendment to its Department

license before conducting such research. The amendment request shall include a

written commitment that the licensee will, before conducting research:

(a)

Obtain prior informed consent from the human research subjects; and

(b)

Obtain prior review and approval of the research activities by an

“Institutional Review Board” in accordance with the meaning of these

terms as defined and described in the Federal Policy;

7.3.2.3 A licensee not authorized pursuant to Part 3, Section 3.11 shall apply for and receive

approval of a specific amendment to its Department license before conducting research

involving human subjects;

7.3.2.4 The research involving human subjects authorized in 7.3.2 shall be conducted using

radioactive material authorized for medical use in the license; and

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

9

7.3.2.5 Nothing in 7.3.2 relieves licensees from complying with the other requirements in Part 7.

7.3.3

Nothing in this part relieves the licensee from complying with applicable FDA, other federal, and

state requirements governing radioactive drugs or devices.

7.3.4

Application for license, amendment, or renewal.

7.3.4.1 An application must be signed by the applicant's or licensee's management.

7.3.4.2 An application for a new or renewal license for medical use of radioactive material as

described in 7.30, 7.32, 7.36, 7.40, 7.42, 7.48 or 7.62 must be made by:

(1)

Filing an original Department Form R-12 (7C) that includes the facility diagram,

equipment, and training and experience qualifications of the Radiation Safety

Officer, Associate Radiation Safety Officer(s), authorized user(s), authorized

medical physicist(s), ophthalmic physicist(s), and authorized nuclear

pharmacist(s); and

(2)

Submitting procedures required by Form R-12 (7C), and 7.12, 7.15, 7.51, 7.58,

7.59, and 7.61, as applicable, and other procedures as requested by the

Department.

7.3.4.3 A request for a license amendment must be made by:

(1)

Submitting an original amendment request in letter format.

(2)

Submitting procedures required by 7.12, 7.15, 7.51, 7.58, 7.59, and 7.61, as

applicable, and other procedures as requested by the Department.

7.3.4.4 In addition to the requirements in 7.3.4.2 and 7.3.4.3, an application for a new license,

renewal license, or amendment for medical use of radioactive material as described in

7.62 must also include:

(1)

Any additional aspects of the medical use of the material that are applicable to

radiation safety that are not addressed in, or differ from:

(a)

Section A through C (7.1 through 7.29);

(b)

Sections D through H (recordkeeping requirements);

(c)

Section I (7.65);

(d)

Appendix 7A, 7B, 7C and 7P;

(2)

Identification of and commitment to follow the applicable radiation safety program

requirements in Sections D through H that are appropriate for the specific 7.62

medical use;

(3)

Any additional specific information on:

(a)

Radiation safety precautions and instructions;

(b)

Methodology for measurement of dosages or doses to be administered

to patients or human research subjects; and

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

10

(c)

Calibration, maintenance, and repair of instruments and equipment

necessary for radiation safety; and

(4)

Any other information requested by the Department in its review of the

application.

7.3.4.5 An applicant that satisfies the requirements specified in Part 3, Section 3.11 may apply

for a Type A specific license of broad scope.

7.3.5

Mobile Medical Service Administrative Requirements.

7.3.5.1 The Department shall license mobile medical services or clients of such services. The

mobile medical service shall be licensed if the service receives, uses or possesses

radioactive material. The client of the mobile medical service shall be licensed if the client

receives or possesses radioactive material to be used by a mobile medical service.

7.3.5.2 Mobile medical service licensees shall obtain a letter signed by the management of each

location where services are rendered that authorizes use of radioactive material at the

client's address of use. This letter shall clearly delineate the authority and responsibility of

both the client and the mobile medical service. If the client is licensed, the letter shall

document procedures for notification, receipt, storage and documentation of transfer of

radioactive material delivered to the client's address for use by the mobile medical

service.

7.3.5.3 A mobile medical service shall not have radioactive material delivered directly from the

manufacturer or the distributor to the client, unless the client has a license allowing

possession of the radioactive material. Radioactive material delivered to the client shall

be received and handled in conformance with the client's license.

7.3.5.4 A mobile medical service shall inform the client's management who is on site at each

client's address of use at the time that radioactive material is being administered.

7.3.5.5 A licensee providing mobile medical services shall retain the letter required in 7.3.5.2 for

3 years after the last provision of service.

7.3.5.6 A mobile medical service licensee shall, at a minimum, maintain the following documents

on each mobile unit:

(1)

The current operating and emergency procedures;

(2)

A copy of the license;

(3)

Copies of the letter required by 7.3.5.2;

(4)

Current calibration records for each survey instrument and diagnostic equipment

or dose delivery device in use; and

(5)

Survey records covering uses associated with the mobile unit during, at a

minimum, the preceding 30 calendar days.

7.3.5.7 The mobile medical service shall designate and manage each area of use in the client’s

facility as a restricted area while radioactive material is present. For each location where

radioactive materials will be routinely used, the licensee shall provide to the Department:

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

11

(1)

A diagram of the location of use, including information about the placement of

required postings; and

(2)

Calculation(s) or survey(s) results that demonstrate compliance with applicable

dose limits in Part 4, Sections 4.14 and 4.15 at the location of use.

7.3.5.8 The mobile medical service shall ensure that:

(1)

Supervision by an authorized user is in accordance with 7.10.1;

(2)

Radiation exposures to the client’s personnel working in the client facility are:

(a)

Below the dose limits to members of the public listed in Part 4, Section

4.14; or

(b)

The client's personnel are instructed as described in Part 10, Section

10.3 and monitored for exposure in accordance with Part 4, Section 4.18

unless the licensee can demonstrate that Section 4.18 does not apply.

7.3.5.9 A mobile medical service licensee shall maintain all records required by Parts 4 and 7 of

these regulations at a location within the Department's jurisdiction that is:

(1)

A single address of use:

(a)

Identified as the records retention location; and

(b)

Staffed at all reasonable hours by individual(s) authorized to provide the

Department with access for purposes of inspection; or

(2)

When no address of use is identified on the license for records retention, the

mobile unit:

(a)

Identified in the license; and

(b)

Whose current client's address of use and area of use schedule is

reported to the Department.

7.3.6

A licensee possessing a Type A specific license of broad scope for medical use, issued under

Part 3 of these regulations, is exempt from:

7.3.6.1 The provisions of 7.3.4.4 regarding the need to file an amendment to the license for

medical uses of radioactive material as described in 7.62;

7.3.6.2 The provisions of 7.4.2 regarding the need to file an amendment before permitting

anyone to work as an authorized user, an authorized nuclear pharmacist or an authorized

medical physicist under the license;

7.3.6.3 The provisions of 7.4.5 regarding additions to or changes in the areas of use at the

addresses identified in the application or on the license;

7.3.6.4 The provisions of 7.5.1 regarding notification to the Department for new authorized users,

new authorized nuclear pharmacists and new authorized medical physicists;

7.3.6.5 The provisions of 7.5.2.1 for an authorized user, an authorized nuclear pharmacist, an

authorized medical physicist or an ophthalmic physicist;

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

12

7.3.6.6 The provisions of 7.5.2.5; and

7.3.6.7 The provisions of 7.14 regarding suppliers for sealed sources.

7.3.7

The Department may, upon application of any interested person or upon its own initiative, grant

such exemptions from the regulations in Part 7 as it determines are authorized by law and will not

endanger life or property or the physical protection of material and are otherwise in the public

interest.

7.4

License amendments.

A licensee shall apply for and must receive a license amendment:

7.4.1

Before it receives, prepares, or uses radioactive material for a type of use that is permitted under

this part but is not authorized on the licensee’s current license issued under this part;

7.4.2

Before it permits anyone to work as an authorized user, authorized medical physicist, ophthalmic

physicist, or an authorized nuclear pharmacist under the license, except:

7.4.2.1 For an authorized user, an individual who meets the requirements in Appendix 7P and

one or more of the following: Section 7D1 of Appendix D, Section 7E1 of Appendix E,

Section 7F1 of Appendix F, Section 7G1 of Appendix 7G, Section 7H1 of Appendix 7H,

Section 7K1 of Appendix K, Section 7J1 of Appendix J, or Section 7M1 of Appendix M;

7.4.2.2 For an authorized nuclear pharmacist, an individual who meets the requirements in

Section 7C1 of Appendix 7C and 7.65;

7.4.2.3 For an authorized medical physicist, an individual who meets the requirements in Section

7B1 of Appendix 7B and 7.65;

7.4.2.4 An individual who is identified as an authorized user, an authorized nuclear pharmacist,

authorized medical physicist, or an ophthalmic physicist:

(1)

On a NRC or Agreement State license or other equivalent permit or license

recognized by the Department that authorizes the use of radioactive material in

medical use or in the practice of nuclear pharmacy;

(2)

On a permit issued by a NRC or Agreement State specific license of broad scope

that is authorized to permit the use of radioactive material in medical use or in the

practice of nuclear pharmacy;

(3)

On a permit issued by a NRC master material licensee that is authorized to

permit the use of radioactive material in medical use or in the practice of nuclear

pharmacy; or

(4)

By a commercial nuclear pharmacy that has been authorized to identify

authorized nuclear pharmacists.

7.4.2.5 A physician, podiatrist, or dentist who used only accelerator-produced radioactive

materials, discrete sources of radium-226, or both, for medical uses or a nuclear

pharmacist who used only accelerator-produced radioactive materials in the practice of

nuclear pharmacy at a Government agency or Federally recognized Indian Tribe before

November 30, 2007 or at all other locations of use before August 8, 2009, or an earlier

date as noticed by the NRC, and for only those materials and uses performed before

these dates.

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

13

7.4.3

Before it changes a Radiation Safety Officer, except as provided in 7.7.3;

7.4.4

Before it permits anyone to work as an Associate Radiation Safety Officer, or before the

Radiation Safety Officer assigns duties to an Associate Radiation Safety Officer that differ from

those for which this individual is authorized on the license;

7.4.5

Before it receives radioactive material in excess of the amount or in a different physical or

chemical form, or receives a different radionuclide than is authorized on the license;

7.4.6

Before it adds to or changes the areas of use identified in the application or on the license,

including areas used in accordance with either 7.30 or 7.32 if the change includes addition or

relocation of either an area where PET radionuclides are produced or a PET radioactive drug

delivery line from the PET radionuclide/PET radioactive drug production area. Other areas of use

where radioactive material is used only in accordance with either 7.30 or 7.32 are exempt;

7.4.7

Before it changes the address(es) of use identified in the application or on the license;

7.4.8

Before it changes statements, representations, and procedures which are incorporated into the

license; or

7.4.9

Before it releases licensed facilities for unrestricted use.

7.4.10 Before it revises procedures required by 7.51, 7.58, 7.59, and 7.61, as applicable, where such

revision reduces radiation safety; and

7.4.11 Before it receives a sealed source from a different manufacturer or of a different model number

than authorized by its license unless the sealed source is used for manual brachytherapy, is listed

in the Sealed Source and Device Registry, and is in a quantity and for an isotope authorized by

the license.

7.5

Notifications and maintenance of records.

7.5.1

A licensee shall provide the Department, no later than 30 days after the date that the licensee

permits an individual to work under the provisions of 7.4.2 as an authorized user, authorized

medical physicist, ophthalmic physicist, or authorized nuclear pharmacist:

7.5.1.1 A copy of the board certification and, as appropriate, verification of completion of:

(1)

Training for the authorized medical physicist under 7B3 of Appendix 7B;

(2)

Any additional case experience required in 7F2.1(2)(f) of Appendix 7F for an

authorized user under 7.36; or

(3)

Device specific training in 7M3 of Appendix 7M for the authorized user under

7.48; or

7.5.1.2 A copy of the Department, NRC or Agreement State license, the permit issued by a NRC

master material licensee, the permit issued by a NRC or Agreement State licensee of

broad scope, the permit issued by a NRC master material license broad scope permittee,

or documentation that only accelerator-produced radioactive materials, discrete sources

of radium-226, or both, were used for medical use or in the practice of nuclear pharmacy

at a Government agency or Federally recognized Indian Tribe before November 30,

2007, or at all other locations of use before August 8, 2009, or an earlier date as noticed

by the NRC for each individual whom the licensee permits to work under the provisions of

this section.

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

14

7.5.2

A licensee shall notify the Department in writing no later than 30 days after:

7.5.2.1 An authorized user, an authorized nuclear pharmacist, a Radiation Safety Officer, an

Associate Radiation Safety Officer, an authorized medical physicist, or ophthalmic

physicist permanently discontinues performance of duties under the license or has a

name change;

7.5.2.2 The licensee permits an individual qualified to be a Radiation Safety Officer under

Appendix 7A and 7.65 to function as a temporary Radiation Safety Officer and to perform

the functions of a Radiation Safety Officer in accordance with 7.7.6.

7.5.2.3 The licensee's mailing address changes;

7.5.2.4 The licensee's name changes, but the name change does not constitute a transfer of

control of the license as described in Part 3, Section 3.15.2 of these regulations; or

7.5.2.5 The licensee has added to or changed the areas of use identified in the application or on

the license where radioactive material is used in accordance with either 7.30 or 7.32 if the

change does not include addition or relocation of either an area where PET radionuclides

are produced or a PET radioactive drug delivery line from the PET radionuclide/PET

radioactive drug production area; or

7.5.2.6 The licensee obtains a sealed source for use in manual brachytherapy from a different

manufacturer or with a different model number than authorized by its license for which it

did not require a license amendment as provided in 7.4.11. The notification must include

the manufacturer and model number of the sealed source, the isotope, and the quantity

per sealed source.

7.5.3

The licensee shall submit the documents required in 7.5.1 and 7.5.2 to the Department.

7.5.4

Maintenance of Records.

Each record required by this part must be legible throughout the retention period specified by

each Department regulation. The record may be the original, a reproduced copy, or a microform

provided that the copy or microform is authenticated by authorized personnel and the microform

is capable of producing a clear copy throughout the required retention period. The record may

also be stored in electronic media with the capability for producing legible, accurate, and

complete records during the required retention period. Records such as letters, drawings, and

specifications must include all pertinent information such as stamps, initials, and signatures. The

licensee shall maintain adequate safeguards against tampering with and loss of records.

7.6

License issuance.

7.6.1

The Department shall issue a license for the medical use of radioactive material if:

7.6.1.1 The applicant has filed Department Form R-12 in accordance with the instructions in

7.3.4;

7.6.1.2 The applicant has paid any applicable fee;

7.6.1.3 The applicant meets the requirements of Part 3 of these regulations; and

7.6.1.4 The Department finds the applicant equipped and committed to observe the safety

standards established by the Department in these regulations for the protection of the

public health and safety.

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

15

7.6.2

The Department shall issue a license for mobile services if the applicant:

7.6.2.1 Meets the requirements in 7.6.1, and in particular 7.3.5; and

7.6.2.2 Assures that individuals to whom radioactive drugs or radiation from implants containing

radioactive material will be administered may be released following treatment in

accordance with 7.26.

Section B – General Administrative Requirements

7.7

Authority and responsibilities for the radiation protection program

7.7.1

In addition to the radiation protection program requirements of Part 4, Section 4.5 of these

regulations, a licensee's management shall approve in writing:

7.7.1.1 Requests for license application, renewal, or amendments before submittal to the

Department;

7.7.1.2 Any individual before allowing that individual to work as an authorized user, authorized

nuclear pharmacist or authorized medical physicist; and

7.7.1.3 Radiation protection program changes that do not require a license amendment and are

permitted under 7.7.

7.7.2

A licensee’s management shall appoint a Radiation Safety Officer (RSO), who agrees in writing to

be responsible for implementing the radiation safety program. The licensee, through the RSO,

shall ensure that radiation safety activities are being performed in accordance with licensee-

approved procedures and regulatory requirements. A licensee’s management may appoint, in

writing, one or more Associate Radiation Safety Officers (ARSO) to support the RSO. The RSO,

with written agreement of the licensee’s management, must assign the specific duties and tasks

to each ARSO. These duties and tasks are restricted to the types of use for which the ARSO is

listed on a license. The RSO may delegate duties and tasks to the ARSO but shall not delegate

the authority or responsibilities for implementing the radiation protection program.

7.7.3

For up to 60 days each year, a licensee may permit an individual qualified to be a Radiation

Safety Officer, under Appendix 7A and 7.65, to function as a temporary Radiation Safety Officer

and to perform the functions of a Radiation Safety Officer, as provided in 7.7.6, if the licensee

takes the actions required in 7.7.2, 7.7.5, 7.7.6, and 7.7.7 and notifies the Department in

accordance with 7.5.2.

7.7.4

A licensee may simultaneously appoint more than one temporary Radiation Safety Officer in

accordance with 7.7.3, if needed to ensure that the licensee has a temporary Radiation Safety

Officer that satisfies the requirements to be a Radiation Safety Officer for each of the different

types of uses of radioactive material permitted by the license.

7.7.5

A licensee shall establish the authority, duties, and responsibilities of the Radiation Safety Officer

in writing.

7.7.6

A licensee shall provide the Radiation Safety Officer sufficient authority, organizational freedom,

time, resources, and management prerogative, to:

7.7.6.1 Identify radiation safety problems;

7.7.6.2 Initiate, recommend, or provide corrective actions;

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

16

7.7.6.3 Stop unsafe operations; and

7.7.6.4 Verify implementation of corrective actions.

7.7.7

A licensee shall retain a record of actions taken under 7.7.1, 7.7.2, and 7.7.5 as follows:

Records of authority and responsibilities for radiation protection programs.

7.7.7.1 A licensee shall retain a record of actions taken by the licensee's management in

accordance with 7.7.1 for 5 years. The record must include a summary of the actions

taken and a signature of licensee management.

7.7.7.2 The licensee shall retain a copy of both authority, duties, and responsibilities of the

Radiation Safety Officer as required by 7.7.5, and a signed copy of each Radiation Safety

Officer's agreement to be responsible for implementing the radiation safety program, as

required by 7.7.2, for the duration of the license. The records must include the signature

of the Radiation Safety Officer and licensee management.

7.7.7.3 For each Associate Radiation Safety Officer appointed under 7.7.2, the licensee shall

retain, for 5 years after the Associate Radiation Safety Officer is removed from the

license, a copy of the written document appointing the Associate Radiation Safety Officer

signed by the licensee's management.

7.8

Radiation safety committee.

7.8.1

Licensees that are authorized for one or more different types of radioactive material use under

7.36, 7.42, 7.48, or 7.62 shall establish a Radiation Safety Committee to oversee all uses of

radioactive material permitted by the license.

7.8.2

The Committee shall:

7.8.2.1 Include:

(1)

An authorized user of each type of use permitted by the license;

(2)

The Radiation Safety Officer

(3)

A representative of the nursing service

(4)

A representative of management who is neither an authorized user nor a

Radiation Safety Officer; and

(5)

Other members as the licensee deems appropriate.

7.8.2.2 Meet as necessary, but at a minimum shall meet at intervals not to exceed 6 months.

7.8.2.3 Maintain minutes of each meeting, including:

(1)

The date of the meeting;

(2)

Members present;

(3)

Members absent; and

(4)

Summary of deliberations and discussions.

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

17

7.9

Radiation protection program changes.

7.9.1

A licensee may revise its radiation protection program without Department approval if:

7.9.1.1 The revision does not require an amendment under 7.4;

7.9.1.2 The revision is in compliance with the regulations and the license;

7.9.1.3 The revision has been reviewed and approved by the Radiation Safety Officer, licensee

management and licensee's Radiation Safety Committee (if applicable); and

7.9.1.4 The affected individuals are instructed on the revised program before the changes are

implemented.

7.9.2

A licensee shall retain a record of each change for 5 years, including

7.9.2.1 A copy of the old and new procedures;

7.9.2.2 The effective date of the change; and

7.9.2.2 The signature of the licensee management that reviewed and approved the change.

7.10

Supervision.

7.10.1 A licensee that permits the receipt, possession, use, or transfer of radioactive material by an

individual under the supervision of an authorized user as allowed by 7.3.1.2(1) shall:

7.10.1.1

In addition to the requirements of Part 10, Section 10.3 of these regulations,

instruct the supervised individual in the licensee's written radiation protection procedures,

written directive procedures, regulations of Part 7, and license conditions with respect to

the use of radioactive material; and

7.10.1.2

Require the supervised individual to follow the instructions of the supervising

authorized user for medical uses of radioactive material, written radiation protection

procedures, written directive procedures, regulations of Part 7, and license conditions

with respect to the medical use of radioactive material.

7.10.2 A licensee that permits the preparation of radioactive material for medical use by an individual

under the supervision of an authorized nuclear pharmacist or physician who is an authorized

user, as allowed by 7.3.1.2(2), shall:

7.10.2.1

In addition to the requirements of Part 10, Section 10.3, instruct the supervised

individual in the preparation of radioactive material for medical use, as appropriate to that

individual's use of radioactive material; and

7.10.2.2

Require the supervised individual to follow the instructions of the supervising

authorized user or authorized nuclear pharmacist regarding the preparation of radioactive

material for medical use, the written radiation protection procedures, the regulations of

Part 7, and license conditions.

7.10.3 Unless physical presence as described in other sections of Part 7 is required, a licensee who

permits supervised activities under 7.10.1 and 7.10.2 shall require an authorized user to be

immediately available by telephone within ten minutes to communicate with the supervised

individual, unless otherwise authorized by the Department with prior written approval.

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

18

7.10.4 A licensee who permits supervised activities under 7.10.1 and 7.10.2 is responsible for the acts

and omissions of the supervising authorized user and supervised individual(s).

7.10.5 A licensee who permits supervised activities under 7.10.1 and 7.10.2 shall require that the

administration of radioactive material or radiation from radioactive material under the supervision

of an authorized user be performed only by:

7.10.5.1

A physician;

7.10.5.2

An individual who meets the requirements of Appendix 7B or 7N;

7.10.5.3

An individual in training in medical physics while under personal supervision of

an individual meeting the requirements of Appendix 7B;

7.10.5.4

An individual in training in nuclear medicine technology while under personal

supervision of an individual meeting the requirements of Appendix 7N; or

7.10.5.5

An individual otherwise authorized in writing by the Department, or through

license condition(s).

7.11

Written directives.

7.11.1 A written directive must be dated and signed by an authorized user, including the signatory's

printed or typed name, before the administration of:

7.11.1.1

I-131 sodium iodide greater than 1.11 MBq (30 µCi), or

7.11.1.2

Any therapeutic dosage of radioactive material, or

7.11.1.3

Any therapeutic dose of radiation from radioactive material.

If, because of the emergent nature of the patient’s condition, a delay in order to provide a

written directive would jeopardize the patient’s health, an oral directive is acceptable. The

information contained in the oral directive must be documented as soon as possible in

writing in the patient’s record. A written directive must be prepared within 48 hours of the

oral directive.

7.11.2 The written directive must contain the patient or human research subject's name and the

following:

7.11.2.1

For an administration of a dosage of radioactive drug containing radioactive

material, the name of the radioactive drug containing radioactive material, dosage, and

route of administration;

7.11.2.2

For gamma stereotactic radiosurgery, the total dose, treatment site, and values

for the target coordinate settings per treatment for each anatomically distinct treatment

site;

7.11.2.3

For teletherapy, the total dose, dose per fraction, number of fractions, and

treatment site;

7.11.2.4

For high dose rate remote afterloading brachytherapy: the radionuclide,

treatment site, dose per fraction, number of fractions, and total dose;

7.11.2.5

For permanent implant brachytherapy:

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

19

(1)

Before implantation: the treatment site, the radionuclide, and the total source

strength: and

(2)

After implantation but before the patient leaves the post treatment recovery area:

the treatment site, the number of sources implanted, the total source strength

implanted, and the date; or

7.11.2.6

For all other brachytherapy, including LDR, MDR, and PDR:

(1)

Before implantation: the treatment site, radionuclide, and dose; and

(2)

After implantation but before completion of the procedure: the radionuclide;

treatment site; number of sources; total source strength and exposure time (or

the total dose); and date.

7.11.3 A written revision to an existing written directive may be made if the revision is dated and signed

by an authorized user before the administration of the dosage of unsealed radioactive material,

the brachytherapy dose, the gamma stereotactic radiosurgery dose, the teletherapy dose, or the

next fractional dose.

7.11.3.1

If, because of the patient's condition, a delay in order to provide a written revision

to an existing written directive would jeopardize the patient's health, an oral revision to an

existing written directive is acceptable. The oral revision must be documented as soon as

possible in the patient's record. A revised written directive must be signed by the

authorized user within 48 hours of the oral revision.

7.11.4 The licensee shall retain a copy of each written directive and/or written revision to an existing

written directive for 3 years.

7.12

Procedures for administrations requiring a written directive.

7.12.1 For any administration requiring a written directive, the licensee shall develop, implement, and

maintain written procedures to provide high confidence that:

7.12.1.1

The patient's or human research subject's identity is verified before each

administration; and

7.12.1.2

Each administration is in accordance with the written directive.

7.12.2 At a minimum, the procedures required by 7.12.1 must address the following items that are

applicable for the licensee's use of radioactive material:

7.12.2.1

Verifying the identity of the patient or human research subject;

7.12.2.2

Verifying that the administration is in accordance with the treatment plan, if

applicable, and the written directive;

7.12.2.3

Checking both manual and computer-generated dose calculations;

7.12.2.4

Verifying that any computer-generated dose calculations are correctly transferred

into the consoles of therapeutic medical units authorized by 7.48 or 7.62.

7.12.2.5

Determining if a medical event, as defined in 7.21, has occurred; and

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

20

7.12.2.6

Determining, for a permanent implant brachytherapy, within 60 calendar days

from the date the implant was performed, the total source strength administered outside

of the treatment site compared to the total source strength documented in the post-

implantation portion of the written directive, unless a written justification of patient

unavailability is documented.

7.12.3 A licensee shall retain a copy of the procedures required under 7.12.1 for the duration of the

license.

7.13

Duties of authorized user and authorized medical physicist.

7.13.1 A licensee shall assure that only authorized users for the type of radioactive material used:

7.13.1.1

Prescribe the radiopharmaceutical dosage and/or dose to be administered

through the issuance of a written directive or reference to the diagnostic clinical

procedures manual; and

7.13.1.2

Direct, as specified in 7.10 and 7.12, or in license conditions, the administration

of radioactive material for medical use to patients or human research subjects;

7.13.1.3

Prepare and administer, or supervise the preparation and administration of

radioactive material for medical use, in accordance with 7.3.1.2(1), 7.3.1.2(2) and 7.10;

7.13.2 A licensee shall assure that only authorized medical physicists perform, as applicable:

7.13.2.1

Measurements and calculations as described in 7.41;

7.13.2.2

Full calibration measurements as described in 7.54, 7.55, and 7.56;

7.13.2.3

Periodic spot checks as described in 7.58, 7.59 and 7.61; and

7.13.2.4

Radiation surveys as described in 7.57.

7.14

Suppliers for sealed sources or devices for medical use.

For medical use, a licensee may only use:

7.14.1 Sealed sources or devices manufactured, labeled, packaged, and distributed in accordance with

a license issued pursuant to Part 3 of these regulations or the equivalent regulations of an

Agreement State or NRC;

7.14.2 Sealed source or devices non-commercially transferred from a Part 7 licensee or an Agreement

State or NRC medical use licensee; or

7.14.3 Teletherapy sources manufactured and distributed in accordance with a license issued pursuant

to Part 3 of these regulations, or the equivalent regulations of an Agreement State or NRC.

Section C – General Technical Requirements

7.15

Quality Control of Diagnostic Equipment.

7.15.1 Each licensee shall establish written quality control procedures for all diagnostic equipment used

for radionuclide studies.

7.15.2 As a minimum, quality control procedures and frequencies shall be:

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

21

7.15.2.1

Those recommended by equipment manufacturers; or

7.15.2.2

Procedures which have been approved by the Department.

7.15.3 The licensee shall conduct quality control of diagnostic equipment in accordance with written

procedures.

7.15.4 A licensee shall retain a record of each quality control test required by the written quality control

procedures for 3 years.

7.16

Possession, use, and calibration of instruments used to measure the activity of unsealed

radioactive material.

7.16.1 For direct measurements performed in accordance with 7.18, a licensee shall possess and use

instrumentation to measure the activity of unsealed radioactive materials prior to administration to

each patient or human research subject.

7.16.2 A licensee shall calibrate the instrumentation required in 7.16.1 in accordance with nationally

recognized standards or the manufacturer's instructions.

7.16.3 In addition to the calibration required in 7.16.2, the licensee shall at a minimum also perform tests

for constancy, linearity, and geometry dependence, as appropriate to demonstrate proper

operation of the instrument.

7.16.4 A licensee shall retain a record of each instrument calibration and test required by 7.16 for 3

years. The record shall include the:

7.16.4.1

Model and serial number of the instrument;

7.16.4.2

Date of the calibration and other tests;

7.16.4.3

Results of the calibration and other tests; and

7.16.4.4

Name of the individual who performed the calibration and other tests.

7.17

Calibration of survey instruments.

7.17.1 A licensee shall calibrate the survey instruments used to show compliance with Part 4 and Part 7

before first use, annually at intervals not to exceed 12 months, and following a repair that affects

the calibration. A licensee shall:

7.17.1.1

Calibrate all scales with readings up to 10 mSv (1000 mrem) per hour with a

radiation source;

7.17.1.2

Calibrate two separate readings on each scale or decade that will be used to

show compliance; and

7.17.1.3

Conspicuously note on the instrument the date of calibration.

7.17.2 A licensee may not use survey instruments if the difference between the indicated exposure rate

and the calculated exposure rate is more than 20 percent.

7.17.3 A licensee shall retain a record of each survey instrument calibration required by 7.17 for 3 years.

The record shall include the:

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

22

7.17.3.1

Model and serial number of the instrument;

7.17.3.2

Date of the calibration;

7.17.3.3

Results of the calibration; and

7.17.3.4

Name of the individual who performed the calibration.

7.18

Determination of dosages of unsealed radioactive material for medical use.

7.18.1 A licensee shall determine and record the activity of each dosage before medical use.

7.18.1.1

For photon-emitting radioactive material, this determination shall be within 30

minutes prior to medical use.

7.18.1.2

For all other radioactive material, this determination shall be within the period

before medical use that is no greater than 10 percent of the physical half-life of the

radioactive material.

7.18.2 For a unit dosage, the determination required by 7.18.1 shall be made by:

7.18.2.1

Direct measurement of radioactivity; or

7.18.2.2

A decay correction, based on the measurement made by:

(1)

A manufacturer or preparer licensed pursuant to Part 3 of these regulations or

equivalent provisions of an Agreement State, or NRC; or

(2)

An NRC or Agreement State licensee for use in research in accordance with a

Radioactive Drug Research Committee-approved protocol or an Investigational

New Drug (IND) protocol accepted by FDA.

(3)

A PET radioactive drug producer licensed under Part 3, Section 3.8.10 or

equivalent NRC or Agreement State requirements.

7.18.3 For other than unit dosages, the determination by 7.18.1 shall be made by:

7.18.3.1

Direct measurement of radioactivity; or

7.18.3.2

Combination of measurement of radioactivity and mathematical calculations; or

7.18.3.3

Combination of volumetric measurements and mathematical calculations, based

on the measurement made by:

(1)

A manufacturer or preparer licensed pursuant to Part 3 of these regulations or

equivalent provisions of an Agreement State, or NRC.

(2)

A PET radioactive drug producer licensed under Part 3, Section 3.8.10 or

equivalent NRC or Agreement State requirements.

7.18.4 Unless otherwise directed by the authorized user, a licensee shall not use a dosage if the dosage

differs from the prescribed dosage by more than 20 percent.

7.18.5 A license shall retain a record of the each dosage determination required by 7.18.1 for 3 years.

The record shall contain the:

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

23

7.18.5.1

Name of the radioactive drug;

7.18.5.2

Patient's or human research subject’s name, and identification number if one has

been assigned;

7.18.5.3

Prescribed dosage;

7.18.5.4

Determined dosage; or a notation that the total activity is less than 1.1 MBq (30

µCi);

7.18.5.5

Date and time of the dosage determination; and

7.18.5.6

Name of the individual who determined the dosage.

7.19

Authorization for calibration, transmission and reference sources.

7.19.1 Any person authorized by 7.3 for medical use of radioactive material may receive, possess, and

use any of the following radioactive material for check, calibration, transmission and reference

use:

7.19.1.1

Sealed sources, not exceeding 1.11 GBq (30 mCi) each, manufactured and

distributed by a person licensed under Part 3, by NRC under 10 CFR 32.74 or equivalent

Agreement State regulations;

7.19.1.2

Sealed sources, not exceeding 1.11 GBq (30 mCi) each, redistributed by a

licensee authorized to redistribute the sealed sources manufactured and distributed by a

person licensed under Part 3, by NRC under 10 CFR 32.74 or equivalent Agreement

State regulations, providing the redistributed sealed sources are in the original packaging

and shielding and are accompanied by the manufacturer’s approved instructions;

7.19.1.3

Any radioactive material with a half-life not longer than 120 days or less in

individual amounts not to exceed 0.56 GBq (15 mCi);

7.19.1.4

Any radioactive material with a half life longer than 120 days in individual

amounts not to exceed the smaller of 7.4 MBq (200 uCi) or 1000 times the quantities in

Part 3 Schedule 3B; or

7.19.1.5

Technetium-99m in amounts as needed.

7.19.2 Radioactive material in sealed sources authorized by this provision shall not be:

7.19.2.1

Used for medical use as defined in 7.2 except in accordance with the

requirements in 7.40; or

7.19.2.1

Combined (i.e., bundled or aggregated) to create an activity greater than the

maximum activity of any single sealed source authorized under 7.19.

7.19.3 A licensee using calibration, transmission, and reference sources in accordance with the

requirements in 7.19.1 or 7.19.2 need not list these sources on a specific medical use license.

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

24

7.20

Requirements for possession of sealed sources and brachytherapy sources.

7.20.1 A licensee in possession of any sealed source or brachytherapy source shall follow the radiation

safety and handling instructions supplied by the manufacturer or equivalent instructions approved

by the Department and shall maintain the instructions for the duration of source use in a legible

form convenient to users.

7.20.2 A licensee in possession of a sealed source shall:

7.20.2.1

Test the source for leakage before its first use unless the licensee has a

certificate from the supplier indicating that the sources was tested within 6 months before

transfer to the licensee; and

7.20.2.2

Test the source for leakage at intervals not to exceed 6 months or at intervals

approved by the Department, an Agreement State, or the NRC in the Sealed Source and

Device Registry.

7.20.2.3

A licensee shall retain records of leak tests required by 7.20.2 for 3 years. The

records must include the model number, and serial number if one has been assigned, of

each source tested; the identity of each source by radionuclide and its estimated activity;

the results of the test; the date of the test; and the name of the individual who performed

the test.

7.20.3 To satisfy the leak test requirements of 7.20, the licensee shall measure the sample so that the

leak test can detect the presence of 185 Bq (0.005 uCi) of radioactive material in the sample.

7.20.4 If the leak test reveals the presence of 0.005 microcurie (185 Bq) or more of removable

contamination, the licensee shall:

7.20.4.1

Immediately withdraw the sealed source from use and store, dispose or cause it

to be repaired in accordance with the requirements of these regulations; and

7.20.4.2

File a written report with the Department within 5 days of receiving the leak test

result, including the model number and serial number, if assigned, of the leaking source,

the radionuclide and its estimated activity, the date and results of the test, and the action

taken.

7.20.5 A licensee in possession of a sealed source or brachytherapy source, except for a gamma

stereotactic radiosurgery source, shall conduct a semi-annual physical inventory of all such

sources. The licensee shall retain each inventory record for 3 years. The inventory records must

contain the model number of each source, and serial number if one has been assigned, the

identity of each source by radionuclide and its estimated activity, the location of each source, and

the name of the individual who performed the inventory.

7.21

Report and notification of a medical event.

7.21.1 A licensee shall report any event as a medical event, except for an event that results from patient

or human research subject intervention, in which:

7.21.1.1

The administration of radioactive material or radiation from radioactive material,

except permanent implant brachytherapy, results in:

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

25

(1)

A dose that differs from the prescribed dose or dose that would have resulted

from the prescribed dosage by more than 0.05 Sv (5 rem) effective dose

equivalent, 0.5 Sv (50 rem) to an organ or tissue, or 0.5 Sv (50 rem) shallow

dose equivalent to the skin; and

(a)

The total dose delivered differs from the prescribed dose by 20 percent

or more;

(b)

The total dosage delivered differs from the prescribed dosage by 20

percent or more or falls outside the prescribed dosage range; or

(c)

The fractionated dose delivered differs from the prescribed dose, for a

single fraction, by 50 percent or more.

(2)

A dose that exceeds 0.05 Sv (5 rem) effective dose equivalent, 0.5 Sv (50 rem)

to an organ or tissue, or 0.5 Sv (50 rem) shallow dose equivalent to the skin from

any of the following:

(a)

An administration of a wrong radioactive drug containing radioactive

material or the wrong radionuclide for a brachytherapy procedure;

(b)

An administration of a radioactive drug containing radioactive material by

the wrong route of administration;

(c)

An administration of a dose or dosage to the wrong individual or human

research subject;

(d)

An administration of a dose or dosage delivered by the wrong mode of

treatment; or

(e)

A leaking sealed source.

(3)

A dose to the skin or an organ or tissue other than the treatment site that

exceeds by:

(a)

0.5 Sievert (50 rem) or more the expected dose to that site from the

procedure if the administration had been given in accordance with the

written directive prepared or revised before administration; and

(b)

50 percent or more the expected dose to that site from the procedure if

the administration had been given in accordance with the written

directive prepared or revised before administration.

7.21.1.2

For permanent implant brachytherapy, the administration of radioactive material

or radiation from radioactive material (excluding sources that were implanted in the

correct site but migrated outside the treatment site) that results in:

(1)

The total source strength administered differing by 20 % or more from the total

source strength documented in the post-implantation portion of the written

directive;

(2)

The total source strength administered outside of the treatment site exceeding 20

% of the total source strength documented in the post-implantation portion of the

written directive; or

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

26

(3)

An administration that includes any of the following:

(a)

The wrong radionuclide;

(b)

The wrong individual or human research subject;

(c)

Sealed source(s) implanted directly into a location discontiguous from

the treatment site, as documented in the post-implantation portion of the

written directive; or

(d)

A leaking sealed source resulting in a dose that exceeds 0.5 Sv (50 rem)

to an organ or tissue.

7.21.2 A licensee shall report any event resulting from intervention of a patient or human research

subject in which the administration of radioactive material or radiation from radioactive material

results, or will result in, unintended permanent functional damage to an organ or a physiological

system, as determined by a physician.

7.21.3 The licensee shall notify by telephone the Department no later than the next calendar day after

discovery of the medical event.

7.21.4 The licensee shall submit a written report to the Department within 15 days after discovery of the

medical event.

7.21.4.1

The written report must include:

(1)

The licensee's name;

(2)

The name of the prescribing physician;

(3)

A brief description of the event;

(4)

Why the event occurred;

(5)

The effect, if any, on the individual(s) who received the administration;

(6)

What actions, if any, have been taken, or are planned to prevent recurrence; and

(7)

Certification that the licensee notified the individual (or the individual's

responsible relative or guardian), and if not, why not.

7.21.4.2

The report may not contain the individual's name or any other information that

could lead to identification of the individual.

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

27

7.21.5 The licensee shall provide notification of the medical event to the referring physician and also

notify the individual who is the subject of the medical event no later than 24 hours after its

discovery, unless the referring physician personally informs the licensee either that he or she will

inform the individual or that, based on medical judgment, telling the individual would be harmful.

The licensee is not required to notify the individual without first consulting the referring physician.

If the referring physician or the affected individual cannot be reached within 24 hours, the

licensee shall notify the individual as soon as possible thereafter. The licensee may not delay any

appropriate medical care for the individual, including any necessary remedial care as a result of

the medical event, because of any delay in notification. To meet the requirements of 7.21.5, the

notification of the individual who is the subject of the medical event may be made instead to that

individual's responsible relative or guardian. If a verbal notification is made, the licensee shall

inform the individual, or appropriate responsible relative or guardian, that a written description of

the event can be obtained from the licensee upon request. The licensee shall provide such a

written description if requested.

7.21.6 Aside from the notification requirement, nothing in this section affects any rights or duties of

licensees and physicians in relation to each other, to individuals affected by the medical event, or

to that individual's responsible relatives or guardians.

7.21.7 A licensee shall:

7.21.7.1

Annotate a copy of the report provided to the Department with the:

(1)

Name of the individual who is the subject of the event; and

(2)

Identification number or if no other identification number is available, the social

security number of the individual who is the subject of the event; and

7.21.7.2

Provide a copy of the annotated report to the referring physician, if other than the

licensee, no later than 15 days after the discovery of the event.

7.22

Notification to the Department of deceased patients or human research subjects

containing radioactive material.

7.22.1 The licensee shall notify the Department by telephone immediately upon discovery that a patient

or human research subject containing radioactive material has died, and it is possible that any

individual could receive exposures in excess of Part 4, section 4.14 as a result of the deceased's

body.

7.22.2 The licensee shall submit a written report to the Department within 30 days after discovery that

the patient or human research subject referenced in 7.22.1 has died. The written report must

include the:

7.22.2.1

Licensee's name;

7.22.2.2

Date of death;

7.22.2.3

Radionuclide, chemical and physical form and calculated activity at time of death;

and

7.22.2.4

Names (or titles) and address(es) of known individuals who might have received

exposures exceeding 5 mSv (500 mrem).

7.22.3 The licensee shall retain a record of each written report required by 7.22 for 3 years.

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

28

7.23

Report and notification of a dose to an embryo/fetus or a nursing child

7.23.1 A licensee shall report any dose to an embryo/fetus that is greater than 5 mSv (500 mrem) dose

equivalent that is a result of an administration of radioactive material or radiation from radioactive

material to a pregnant individual unless the dose to the embryo/fetus was specifically approved,

in advance, by the authorized user.

7.23.2 A licensee shall report any dose to a nursing child, that was not specifically approved, in advance,

by the authorized user, that is a result of an administration of radioactive material to a breast

feeding individual that:

7.23.2.1

Is greater than 5 millisievert (500 mrem) total effective dose equivalent; or

7.23.2.2

Has resulted in unintended permanent functional damage to an organ or a

physiological system of the child, as determined by a physician.

7.23.3 The licensee shall notify by telephone the Department no later than the next calendar day after

discovery of a dose to the embryo/fetus or nursing child that requires a report in 7.23.1 or 7.23.2.

7.23.4 The licensee shall submit a written report to the Department within 15 days after discovery of a

dose to the embryo/fetus or nursing child that requires a report in 7.23.1 or 7.23.2.

7.23.4.1

The written report must include:

(1)

The licensee's name;

(2)

The name of the prescribing physician;

(3)

A brief description of the event;

(4)

Why the event occurred;

(5)

The effect on the embryo/fetus or the nursing child;

(6)

What actions, if any, have been taken, or are planned, to prevent recurrence; and

(7)

Certification that the licensee notified the pregnant individual or mother (or the

mother's or child's responsible relative or guardian), and if not, why not.

7.23.4.2

The report must not contain the individual's or child's name or any other

information that could lead to identification of the individual or child.

7.23.5 The licensee shall provide notification of the event to the referring physician and also notify the

pregnant individual or mother, both hereafter referred to as the mother, no later than 24 hours

after discovery of an event that would require reporting under 7.23.1 or 7.23.2, unless the

referring physician personally informs the licensee either that he or she will inform the mother or

that, based on medical judgment, telling the mother would be harmful. The licensee is not

required to notify the mother without first consulting with the referring physician. If the referring

physician or mother cannot be reached within 24 hours, the licensee shall make the appropriate

notifications as soon as possible thereafter. The licensee may not delay any appropriate medical

care for the embryo/fetus or for the nursing child, including any necessary remedial care as a

result of the event, because of any delay in notification. To meet the requirements of 7.23.5, the

notification may be made to the mother's or child's responsible relative or guardian instead of the

mother, when appropriate. If a verbal notification is made, the licensee shall inform the mother, or

the mother's or child's responsible relative or guardian, that a written description of the event can

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

29

be obtained from the licensee upon request. The licensee shall provide such a written description

if requested.

7.23.6 A licensee shall:

7.23.6.1

Annotate a copy of the report provided to the Department with the:

(1)

Name of the pregnant individual or the nursing child who is the subject of the

event; and

(2)

Identification number or if no other identification number is available, the social

security number of the individual who is the subject of the event.

7.23.7 A copy of the record required under 7.23.6 shall be provided to the referring physician, if other

than the licensee, within 15 days after discovery of the event.

7.24

Labeling of vials and syringes.

7.24.1 A licensee shall require each individual preparing or handling a vial that contains a

radiopharmaceutical to keep the vial in a vial radiation shield.

7.24.2 Each syringe and vial that contains a radioactive drug shall be labeled to identify the radioactive

drug, to include the isotope and amount of radioactivity. Each syringe shield and vial shield shall

also be labeled unless the label on the syringe or vial is visible when shielded.

7.25

Surveys for contamination and ambient exposure rate.

7.25.1 Surveys required by 7.25.2 and 7.25.3 are in addition to surveys required by Part 4.

7.25.2 Daily Survey Requirements

7.25.2.1

At the end of each day of use, a licensee shall survey with an exposure rate

instrument, all areas where radioactive drugs containing radioactive material requiring a

written directive were prepared for use or administered.

(1)

A licensee does not need to perform the surveys required by 7.25.2.1 in an area

where patients or human research subjects are confined when they cannot be

released pursuant to 7.26.

7.25.2.2

At the end of each day of use, a licensee shall survey for removable

contamination all areas where generators and bulk radioactive drugs are prepared for

use. An instrument capable of detecting 33.3 becquerels (2000 dpm) of contamination on

each wipe sample shall be used.

7.25.3 Weekly Survey Requirements

7.25.3.1

At least once each week, a licensee shall survey, with an exposure rate

instrument, all areas where radioactive drugs or radioactive wastes are stored.

7.25.3.2

At least once each week, a licensee shall survey for removable contamination in

all areas where radioactive materials other than sealed sources as defined in Part 7 are

stored. An instrument capable of detecting 33.3 becquerels (2000 dpm) of contamination

on each wipe sample shall be used.

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

30

7.25.4 A licensee shall establish action levels for the surveys required by 7.25.2 and 7.25.3 and shall

require that the individual performing the survey immediately notify the Radiation Safety Officer if

action levels are exceeded.

7.25.5 A licensee shall retain a record of each survey required by 7.25.1, 7.25.2 and 7.25.3 for 3 years.

The record must include:

7.25.5.1

The date of the survey;

7.25.5.2

The results of the survey;

7.25.5.3

The instrument used to make the survey (including, if applicable, that the

instrument was checked for consistent response with a dedicated check source prior to

each daily use); and

7.25.5.4

The name of the individual who performed the survey.

7.26

Release of individuals containing unsealed radioactive material or implants containing

radioactive material.

7.26.1 A licensee may authorize the release from the licensee’s control of any individual who has been

administered radioactive drugs or permanent implants containing radioactive material if the total

effective dose equivalent to any other individual from exposure to the released individual is not

likely to exceed 5 mSv (0.5 rem).1

1 Appendix U of U.S. Nuclear Regulatory Commission NUREG-1556, Vol. 9, “Consolidated Guidance About Materials Licenses:

Program Specific Guidance About Medical Licenses” describes methods for calculating doses to other individuals and contains

tables of activities not likely to cause doses exceeding 5 mSv (0.5 rem).

7.26.2 A licensee shall provide the released individual or the individual’s parent or guardian with

instructions, including written instructions on the actions recommended to maintain doses to other

individuals as low as is reasonably achievable if the total effective dose equivalent to any other

individual is likely to exceed 1 mSv (0.1 rem).

7.26.2.1

If the total effective dose equivalent to a nursing infant or child could exceed 1

mSv (0.1 rem) assuming there were no interruption in breast-feeding, the instructions

shall also include:

(1)

Guidance on the interruption or discontinuation of breast-feeding; and

(2)

Information on the potential consequences, if any, of failure to follow the

guidance.

7.26.3 If the total effective dose equivalent to a nursing infant or child could exceed 5 mSv (0.5 rem)

from continued breast-feeding, the licensee shall maintain a record that the instructions required

by 7.26.2 were provided to a breast-feeding woman.

7.26.4 The licensee shall maintain a record of the basis for authorizing the release of an individual in

accordance with 7.26, if the total effective dose equivalent is calculated by:

7.26.4.1

Using the retained activity rather than the administered activity;

7.26.4.2

Using an occupancy factor less than 0.25 at 1 meter;

7.26.4.3

Using the biological or effective half-live; and

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

31

7.26.4.4

Considering the shielding by tissue.

7.26.5 The records required by 7.26.3 and 7.26.4 must be retained for 3 years after the date of release

of the individual.

7.26.6 Reports of Patient Departure Prior to Authorized Release.

7.26.6.1

The licensee shall notify the Department by telephone immediately upon

discovery that a patient or human research subject has departed from the licensee's

facility without authorization under 7.26.

7.26.6.2

The licensee shall submit a written report to the Department within 30 days after

discovery of the unauthorized departure. The written report must include:

(1)

The licensee's name;

(2)

The date and time of the unauthorized departure;

(3)

The projected date and time when release would have occurred;

(4)

The address of the patient's or human research subject's home or anticipated

destination following departure;

(5)

The radionuclide, chemical and physical form and calculated activity at time of

release;

(6)

The apparent reason(s) for the departure prior to authorized release; and

(7)

A description of any changes in the licensee's patient release criteria or patient

instructions that are designed to avoid a recurrence of such an event.

7.27

Mobile nuclear medicine service technical requirements.

A licensee providing mobile nuclear medicine service shall:

7.27.1 Transport to each client’s address of use only syringes or vials containing prepared drugs or

radioactive materials that are intended for reconstitution of radioactive drug kits;

7.27.2 Bring into each client’s address of use all radioactive material to be used and, before leaving,

remove all unused radioactive material and associated radioactive waste;

7.27.3 Secure or keep under constant surveillance and immediate control all radioactive material when

in transit or at a client’s address of use;

7.27.4 Check instruments used to measure the activity of unsealed radioactive material for proper

function before medical use at each client's address or on each day of use, whichever is more

frequent. At a minimum, the check for proper function shall include a constancy check;

7.27.5 Check survey instruments for consistent response with a dedicated check source before use at

each client's address;

7.27.6 Prior to leaving a client’s address of use, perform area surveys and survey for removable

contamination in all areas of use, to ensure compliance with Part 4 of these regulations; and

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

32

7.27.7 Retain a record of each survey required by 7.27.6 for 3 years. The record must include the date

of the survey, the results of the survey, the instrument used to make the survey, and the name of

the individual who performed the survey.

7.28

Storage of Volatiles and Gases.

7.28.1 A licensee shall store volatile radioactive materials and radioactive gases in a radiation shield and

container.

7.28.2 A licensee shall store and use a multi-dose container in a properly functioning fume hood.

7.28.3 A licensee who administers radioactive aerosols or gases shall do so with a system that will keep

airborne concentrations within the limits prescribed in Part 4 of these regulations.

7.28.3.1

The system shall either be directly vented to the atmosphere through an air

exhaust or provide for collection and decay or disposal of the aerosol or gas in a shielded

container.

7.28.3.2

A licensee shall check the operation of collection systems monthly. Records of

these checks shall be maintained for 3 years.

7.29

Decay-in-storage.

7.29.1 A licensee may hold radioactive material with a physical half-life of less than or equal to 120 days

for decay-in-storage before disposal without regard to its radioactivity if it:

7.29.1.1

Monitors radioactive material at the surface before disposal and determines that

its radioactivity cannot be distinguished from the background radiation level with an

appropriate radiation detection survey meter set on its most sensitive scale and with no

interposed shielding; and

7.29.1.2

Removes or obliterates all radiation labels, except for radiation labels on

materials that are within containers and that will be managed as biomedical waste after

they have been released from the licensee; and

7.29.2 Records of Decay-in-Storage.

A licensee shall retain a record of each disposal permitted under 7.29.1 as follows:

7.29.2.1

A licensee shall maintain records of the disposal of licensed materials, as

required by 7.29, for 3 years. The record must include the date of the disposal, the survey

instrument used, the background radiation level, the radiation level measured at the

surface of each waste container, and the name of the individual who performed the

survey.

Section D – Unsealed Radioactive Material – Written Directive Not Required

7.30

Use of unsealed radioactive material for uptake, dilution, and excretion studies for which a

written directive is not required.

7.30.1 Except for quantities that require a written directive under 7.11.2, a licensee may use any

unsealed radioactive material prepared for medical use for uptake, dilution, or excretion studies

that is:

7.30.1.1

Obtained from:

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

33

(1)

A manufacturer or preparer licensed under Part 3, Section 3.12.10 or equivalent

regulations of an Agreement State, or NRC; or;

(2)

A PET radioactive drug producer licensed under Part 3, Section 3.8.10 or

equivalent regulations of an Agreement State or NRC; or

7.30.1.2

Excluding production of PET radionuclides, prepared by:

(1)

An authorized nuclear pharmacist;

(2)

A physician who is an authorized user and who meets the requirements specified

in Appendix 7E, or Appendix 7F and Section 7E3.1(2)(g) of Appendix 7E; or

(3)

An individual under the supervision, as specified in 7.10, of the authorized

nuclear pharmacist in 7.30.1.2(1) or the physician who is an authorized user in

7.30.1.2(2); or

7.30.1.3

Obtained from and prepared by a Department, Agreement State, or NRC

licensee for use in research in accordance with a Radioactive Drug Research Committee-

approved protocol or an Investigational New Drug (IND) protocol accepted by FDA; or

7.30.1.4

Prepared by the licensee for use in research in accordance with a Radioactive

Drug Research Committee-approved application or an Investigational New Drug (IND)

protocol accepted by FDA.

7.30.2 Training For Uptake, Dilution, And Excretion Studies.

The licensee shall require an authorized user of unsealed radioactive material for the uses

authorized under 7.30 to meet the requirements of Appendix 7D.

7.31

Reserved

7.32

Use of unsealed radioactive material for imaging and localizations studies for which a

written directive is not required.

Except for quantities that require a written directive under 7.11, a licensee may use any unsealed

radioactive material prepared for medical use for imaging and localization studies that is:

7.32.1 Obtained from:

7.32.1.1

A manufacturer or preparer licensed pursuant to Part 3, Section 3.12.10 or

equivalent regulations of an Agreement State, or NRC; or

7.32.1.2

A PET radioactive drug producer licensed under Part 3, Section 3.8.10; or

7.32.2 Excluding production of PET radionuclides, prepared by:

7.32.2.1

An authorized nuclear pharmacist;

7.32.2.2

A physician who is an authorized user and who meets the requirements specified

in Appendix 7E, or Appendix 7F and 7E3.1(2)(g); or

7.32.2.3

An individual under the supervision, as specified in 7.10, of the authorized

nuclear pharmacist in 7.32.2.1 or the physician who is an authorized user in 7.32.2.2;

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

34

7.32.3 Obtained from and prepared by a Department, Agreement State, or NRC licensee for use in

research in accordance with a Radioactive Drug Research Committee-approved protocol or an

Investigational New Drug (IND) protocol accepted by FDA; or

7.32.4 Prepared by the licensee in accordance with a Radioactive Drug Research Committee-approved

application or an Investigational New Drug (IND) protocol accepted by FDA for use in research.

7.32.5 Authorized User Training for Imaging and Localization Studies for which a Written Directive is Not

Required.

The licensee shall require an authorized user of an unsealed radioactive material for the uses

authorized under 7.32 to meet the requirements of Appendix 7E.

7.33

Permissible molybdenum-99, strontium-82, and strontium-85 concentrations.

7.33.1 A licensee may not administer to humans a radioactive drug that contains:

7.33.1.1

More than 0.15 kBq of molybdenum-99 per MBq of technetium-99m (0.15 µCi of

99Mo per mCi of 99mTc); or

7.33.1.2

More than 0.02 kBq of strontium-82 per MBq of rubidium-82 chloride injection

(0.02 µCi of 82Sr per mCi of 82Rb chloride); or more than 0.2 kBq of strontium-85 per

MBq of rubidium-82 chloride injection (0.2 µCi of 85Sr per mCi of 82Rb).

7.33.2 A licensee that uses molybdenum-99/technetium-99m generators for preparing a technetium-99m

radioactive drug shall measure the molybdenum-99 concentration in each eluate from a generator

to demonstrate compliance with 7.33.1.

7.33.3 A licensee that uses a strontium-82/rubidium-82 generator for preparing a rubidium-82 radioactive

drug shall, before the first patient use of the day, measure the concentration of radionuclides

strontium-82 and strontium-85 to demonstrate compliance with 7.33.1.

7.33.4 If a licensee is required to measure the molybdenum-99 concentration or strontium-82 and

strontium-85 concentrations, the licensee shall retain a record of each measurement as follows:

7.33.4.1

A licensee shall maintain a record of the molybdenum-99 concentration or

strontium-82 and strontium-85 concentration tests required by 7.33.2 and 7.33.3 for 3

years. The record must include:

(1)

For each measured elution of technetium-99m, the ratio of the measures

expressed as kilobecquerel of molybdenum-99 per megabecquerel of

technetium-99m (or microcuries of molybdenum per millicurie of technetium), the

time and date of the measurement, and the name of the individual who made the

measurement; or

(2)

For each measured elution of rubidium-82, the ratio of the measures expressed

as kilobecquerel of strontium-82 per megabecquerel of rubidium-82 (or

microcuries of strontium-82 per millicurie of rubidium), kilobecquerel of strontium-

85 per megabecquerel of rubidium-82 (or microcuries of strontium-85 per

millicurie of rubidium), the time and date of the measurement, and the name of

the individual who made the measurement.

7.33.5 The licensee shall report any measurement that exceeds the limits in 7.33.1 at the time of

generator elution, as follows:

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

35

Report and notification for an eluate exceeding permissible molybdenum-99, strontium-82, and

strontium-85 concentrations.

7.33.5.1

The licensee shall notify by telephone the Department and the distributor of the

generator within 7 calendar days after discovery that an eluate exceeded the permissible

concentration listed in 7.33.1 at the time of generator elution. The telephone report to the

Department must include the manufacturer, model number, and serial number (or lot

number) of the generator; the results of the measurement; the date of the measurement;

whether dosages were administered to patients or human research subjects, when the

distributor was notified, and the action taken.

7.33.5.2

The licensee shall submit a written report to the Department within 30 calendar

days after discovery of an eluate exceeding the permissible concentration at the time of

generator elution. The written report must include the action taken by the licensee; the

patient dose assessment; the methodology used to make this dose assessment if the

eluate was administered to patients or human research subjects; and the probable cause

and an assessment of failure in the licensee’s equipment, procedures or training that

contributed to the excessive readings if an error occurred in the licensee’s breakthrough

determination; and the information in the telephone report as required by 7.33.5.1.

7.34

Aerosols and gases.

Provided the conditions of 7.28 are met, a licensee shall use radioactive aerosols or gases only if

specific application is made to and approved by the Department.

7.35

Reserved

Section E – Unsealed Radioactive Material – Written Directive Required

7.36

Use of unsealed radioactive material for which a written directive is required.

7.36.1 A licensee may use any unsealed radioactive material identified in 7F2.1(2)(f) prepared for

medical use and for which a written directive is required that is:

7.36.1.1

Obtained from:

(1)

A manufacturer or preparer licensed under Part 3, Section 3.12.10 or equivalent

regulations of NRC or an Agreement State; or

(2)

A PET radioactive drug producer licensed under Part 3, Section 3.8.10 or

equivalent Agreement State or NRC regulations; or

7.36.1.2

Excluding production of PET radioactive material, prepared by:

(1)

An authorized nuclear pharmacist;

(2)

A physician who is an authorized user and who meets the requirements specified

in Appendix 7E, or Appendix 7F; or

(3)

An individual under the supervision, as specified in 7.10, of the authorized

nuclear pharmacist in 7.36.1.2(1) or the physician who is authorized under

7.36.1.2(2); or

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

36

7.36.1.3

Obtained from and prepared by a Department, Agreement State, or NRC

licensee for use in research in accordance with an Investigational New Drug (IND)

protocol accepted by FDA; or

7.36.1.4

Prepared by the licensee for use in research in accordance with an

Investigational New Drug (IND) protocol accepted by FDA.

7.36.2 Training For Use Of Any Unsealed Radioactive Material For Diagnostic Or Therapeutic Medical

Use For Which A Written Directive Is Required.

The licensee shall require an authorized user of an unsealed radioactive material for diagnostic or

therapeutic medical use for which a written directive is required under 7.36 to meet the

requirements of Appendix 7F.

7.36.3 Training For Oral Administration of < / = 1.22 GBq 131I (33 mCi) Sodium Iodide Requiring A

Written Directive.

The licensee shall require an authorized user of an unsealed radioactive material for oral

administration of < / = 1.22 GBq 131I (33 mCi) sodium iodide requiring a written directive under

7.36 to meet the requirements of Appendix 7G.

7.36.4 Training For Oral Administration Of > 1.22 GBq 131I (33 mCi) Sodium Iodide Requiring A Written

Directive.

The licensee shall require an authorized user of an unsealed radioactive material for oral

administration of > 1.22 GBq 131I (33 mCi) sodium iodide requiring a written directive under 7.36

to meet the requirements of Appendix 7H.

7.36.5 Training For Parenteral Administration Requiring A Written Directive.

The licensee shall require an authorized user of an unsealed radioactive material for parenteral

administration requiring a written directive under 7.36 to meet the requirements of Appendix 7I.

7.37

Safety instruction.

In addition to the requirements of Part 10 of these regulations:

7.37.1 A licensee shall provide radiation safety instruction, initially and at least annually, to personnel

caring for patients or human research subjects who cannot be released in accordance with 7.26.

To satisfy this requirement, the instruction must be commensurate with the duties of the

personnel and include:

7.37.1.1

Patient or human research subject control;

7.37.1.2

Visitor control, including:

(1)

Routine visitation to hospitalized individuals in accordance with Part 4, Section

4.14.1.1 of these regulations; and

(2)

Visitation authorized in accordance with Part 4, Section 4.14.2;

7.37.1.3

Contamination control;

7.37.1.4

Waste control; and

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

37

7.37.1.5

Notification of the RSO, or his or her designee, and an authorized user if the

patient or the human research subject has a medical emergency or dies.

7.37.2 A licensee shall retain a record of individuals receiving safety instructions required by 7.37 and

maintain such records for 3 years. The record must include a list of the topics covered, the date of

the instruction, the name(s) of the attendee(s), and the name(s) of the individual(s) who provided

the instruction.

7.38

Safety precautions.

7.38.1 For each patient or human research subject who cannot be released under 7.26, a licensee shall:

7.38.1.1

Quarter the patient or the human research subject either in:

(1)

A private room with a private sanitary facility; or

(2)

A room, with a private sanitary facility, with another individual who also has

received therapy with unsealed radioactive material and who also cannot be

released in accordance with 7.26; and

7.38.1.2

Visibly post the patient's or the human research subject’s room with a

“Radioactive Materials” sign.

7.38.1.3

Note on the door or in the patient's or the human research subject’s chart where

and how long visitors may stay in the patient's or the human research subject’s room;

and

7.38.1.4

Either monitor material and items removed from the patient's or the human

research subject’s room to determine that their radioactivity cannot be distinguished from

the natural background radiation level with a radiation detection survey instrument set on

its most sensitive scale and with no interposed shielding, or handle the materials and

items as radioactive waste.

7.38.2 A licensee shall notify the RSO, or his or her designee, and an authorized user as soon as

possible if the patient or human research subject has a medical emergency or dies.

7.39

Reserved.

Section F – Sealed Sources for Diagnosis

7.40

Use of sealed sources and medical devices for diagnosis.

7.40.1 A licensee must use only sealed sources that are not in medical devices for diagnostic medical

uses if the sealed sources are approved in the Sealed Source and Device Registry for diagnostic

medicine. The sealed sources may be used for diagnostic medical uses that are not explicitly

listed in the Sealed Source and Device Registry but must be used in accordance with the

radiation safety conditions and limitations described in the Sealed Source and Device Registry.

7.40.2 A licensee must only use medical devices containing sealed sources for diagnostic medical uses

if both the sealed sources and medical devices are approved in the Sealed Source and Device

Registry for diagnostic medical uses. The diagnostic medical devices may be used for diagnostic

medical uses that are not explicitly listed in the Sealed Source and Device Registry but must be

used in accordance with the radiation safety conditions and limitations described in the Sealed

Source and Device Registry.

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

38

7.40.3 Sealed sources and devices for diagnostic medical uses may be used in research in accordance

with an active Investigational Device Exemption (IDE) application accepted by the U.S. Food and

Drug Administration provided the requirements of 7.14.1 are met.

7.40.4 Training for use of sealed sources and medical devices for diagnosis.

The licensee shall require an authorized user under 7.40 to meet the requirements of Appendix

7J.

Section G – Manual Brachytherapy

7.41

Calibration measurements of brachytherapy sources.

7.41.1 Before the first medical use of a brachytherapy source, a licensee shall have:

7.41.1.1

Determined the source output or activity using a dosimetry system that meets the

requirements of 7.53;

7.41.1.2

Determined source positioning accuracy within applicators; and

7.41.1.3

Used published protocols currently accepted by nationally recognized bodies to

meet the requirements of 7.41.1.1 and 7.41.1.2.

7.41.2 Instead of a licensee making its own measurements as required in 7.41.1, the licensee may use

measurements provided by the source manufacturer or by a calibration laboratory accredited by

the American Association of Physicists in Medicine that are made in accordance with 7.41.1.

7.41.3 A licensee shall mathematically correct the outputs or activities determined in 7.41.1 for physical

decay at intervals consistent with 1 percent physical decay.

7.41.4 An authorized medical physicist shall perform or review the measurements and calculations made

pursuant to 7.41.1, 7.41.2, or 7.41.3.

7.41.5 A licensee shall retain a record of each calibration as follows:

7.41.5.1

A licensee shall maintain a record of the calibrations of brachytherapy sources

required by 7.41.1 for 3 years after the last use of the source.

7.41.5.2

The record must include:

(1)

The date of the calibration;

(2)

The manufacturer's name, model number, and serial number for the source and

the instruments used to calibrate the source;

(3)

The source output or activity;

(4)

The source positioning accuracy within the applicators; and

(5)

The name of the individual, the source manufacturer, or the calibration laboratory

that performed the calibration.

7.41.6 Strontium-90 sources for ophthalmic treatments.

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

39

7.41.6.1

Licensees who use strontium-90 for ophthalmic treatments must ensure that

certain activities as specified in 7.41.6.2 are performed by either:

(1)

An authorized medical physicist; or

(2)

An individual who:

(a)

Is identified as an ophthalmic physicist on a specific medical use license

issued by NRC or an Agreement State; permit issued by a NRC or

Agreement State broad scope medical use licensee; medical use permit

issued by a NRC master material licensee; or permit issued by a NRC

master material license broad scope medical use permittee; and

(b)

Holds a master’s or doctor’s degree in physics, medical physics, other

physical sciences, engineering, or applied mathematics from an

accredited college or university; and

(c)

Has successfully completed 1 year full-time training in medical physics

and an additional year of full-time work experience under the supervision

of a medical physicist; and

(d)

Has documented training in:

(i)

The creation, modification, and completion of written directives;

(ii)

Procedures for administrations requiring a written directive; and

(iii)

Performing the calibration measurements of brachytherapy

sources as detailed in 7.41.1 through 7.41.5.

7.41.6.2

The individuals who are identified in 7.41.6.1 must:

(1)

Calculate the activity of each strontium-90 source that is used to determine the

treatment times for ophthalmic treatments. The decay must be based on the

activity determined under 7.41.1 through 7.41.5; and

(2)

Assist the licensee in developing, implementing, and maintaining written

procedures to provide high confidence that the administration is in accordance

with the written directive. These procedures must include the frequencies that the

individual meeting the requirements in 7.41.6.1 will observe treatments, review

the treatment methodology, calculate treatment time for the prescribed dose, and

review records to verify that the administrations were in accordance with the

written directives.

7.41.6.3

Licensees must retain a record of the activity of each strontium-90 source as

follows:

(1)

A licensee shall maintain a record of the activity of a strontium-90 source

required by 7.41.6 for the life of the source.

(2)

The record must include:

(a)

The date and initial activity of the source as determined under 7.41.1

through 7.41.5; and

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

40

(b)

For each decay calculation, the date and the source activity as

determined under 7.41.6.

7.42

Use of sealed sources for manual brachytherapy.

7.42.1 A licensee must use only brachytherapy sources:

7.42.1.1

Approved in the Sealed Source and Device Registry for manual brachytherapy

use. The manual brachytherapy sources may be used for manual brachytherapy uses

that are not explicitly listed in the Sealed Source and Device Registry, but must be used

in accordance with the radiation safety conditions and limitations described in the Sealed

Source and Device Registry; or

7.42.1.2

In research to deliver therapeutic doses for medical use in accordance with an

active Investigational Device Exemption (IDE) application accepted by the FDA provided

the requirements of 7.14.1 are met.

7.42.2 Authorized User Training For Use Of Sealed Sources For Manual Brachytherapy.

The licensee shall require an authorized user under 7.42 to meet the requirements of Appendix

7K.

7.42.3 Authorized User Training For Use Of Strontium-90 Sealed Sources For Ophthalmic Uses.

The licensee shall require an authorized user of strontium-90 sealed sources for ophthalmic uses

under 7.42 to meet the requirements of Appendix 7L.

7.43

Safety instruction.

In addition to the requirements of Part 10 of these regulations:

7.43.1 The licensee shall provide radiation safety instruction, initially and at least annually, to personnel

caring for patients or human research subjects that are undergoing implant therapy and cannot

be released in accordance with 7.26.

7.43.2 The instruction required by 7.43.1 shall be commensurate with the duties of the personnel and

include:

7.43.2.1

Size and appearance of the brachytherapy sources;

7.43.2.2

Safe handling and shielding instructions in case of a dislodged source;

7.43.2.3

Patient or human research subject control;

7.43.2.4

Visitor control, including both;

(1)

Routine visitation to hospitalized individuals in accordance with Part 4, Section

4.14.1.1; and

(2)

Visitation authorized in accordance with Part 4, Section 4.14.3; and

7.43.2.5

Notification of the RSO, or his or her designee, and the authorized user if the

patient or the human research subject dies or has a medical emergency.

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

41

7.43.3 A licensee shall retain a record of individuals receiving safety instructions required by 7.43.1 and

maintain such records for 3 years. The record must include a list of the topics covered, the date of

the instruction, the names(s) of the attendee(s), and the name(s) of the individual(s) who provided

the instruction.

7.44

Safety precautions.

7.44.1 For each patient or the human research subject that is receiving brachytherapy and cannot be

released in accordance with 7.26, a licensee shall:

7.44.1.1

Not place the patient or the human research subject in the same room with a

patient who is not receiving radiation therapy;

7.44.1.2

Visibly post the patient's or human research subject’s door with a “Caution:

Radioactive Material” sign and note on the door or on the patient's or human research

subject’s chart where and how long visitors may stay in the patient's or human research

subject’s room.

7.44.2 A licensee shall have emergency response equipment available near each treatment room to

respond to a source that inadvertently becomes:

7.44.2.1

Dislodged from the patient; or

7.44.2.2

Lodged within the patient following removal of the source applicators.

7.44.3 A licensee shall notify the RSO, or his or her designee, and an authorized user as soon as

possible if the patient or human research subject has a medical emergency or dies.

7.45

Brachytherapy sources inventory.

7.45.1 A licensee shall maintain accountability at all times for all brachytherapy sources in storage or

use.

7.45.2 As soon as possible after removing brachytherapy sources from a patient or a human research

subject, a licensee shall return brachytherapy sources to a secure storage area and count or

otherwise verify the number returned to ensure that all sources taken from the storage area have

been returned.

7.45.3 A licensee shall maintain a record of brachytherapy source accountability for 3 years.

7.45.3.1

For temporary implants, the record must include:

(1)

The number and activity of sources removed from storage, the time and date

they were removed from storage, the name of the individual who removed them

from storage, and the location of use; and

(2)

The number and activity of sources returned to storage, the time and date they

were returned to storage, and the name of the individual who returned them to

storage.

7.45.3.2

For permanent implants, the record must include:

(1)

The number and activity of sources removed from storage, the date they were

removed from storage, and the name of the individual who removed them from

storage;

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

42

(2)

The number and activity of sources not implanted, the date they were returned to

storage, the date they were returned to storage, and the name of the individual

who returned them to storage; and

(3)

The number and activity of sources permanently implanted in the patient or

human research subject.

7.46

Surveys after source implant and removal.

7.46.1 Immediately after implanting sources in a patient or a human research subject, the licensee shall

perform a survey to locate and account for all sources that have not been implanted.

7.46.2 Immediately after removing the last temporary implant source from a patient or a human research

subject, the licensee shall perform a radiation survey of the patient with a radiation detection

survey instrument to confirm that all sources have been removed. The licensee shall not release

from confinement for medical care a patient treated by temporary implant until all sources have

been removed.

7.46.3 A licensee shall maintain a record of patient surveys which demonstrate compliance with 7.46.1

and 7.46.2 for 3 years. Each record must include the date and results of the survey, the survey

instrument used, and the name of the individual who made the survey.

7.47

Therapy-related computer systems.

7.47.1 The licensee shall perform acceptance testing on the treatment planning system of therapy-

related computer systems in accordance with published protocols accepted by nationally

recognized bodies.

7.47.2 At a minimum, the acceptance testing required by 7.47.1 shall include, as applicable, verification

of:

7.47.2.1

The source-specific input parameters required by the dose calculation algorithm;

7.47.2.2

The accuracy of dose, dwell time, and treatment time calculations at

representative points;

7.47.2.3

The accuracy of isodose plots and graphic displays; and

7.47.2.4

The accuracy of the software used to determine radioactive source positions

from radiographic images.

Section H - Photon Emitting Remote Afterloader Units, Teletheraphy Units, and Gamma

Stereotactic Radiosurgery Units

7.48

Use of a sealed source in a remote afterloader unit, teletherapy unit, or gamma

stereotactic radiosurgery unit.

7.48.1 A licensee must only use sealed sources:

7.48.1.1

Approved and as provided for in the Sealed Source and Device Registry in

photon emitting remote afterloader units, teletherapy units, or gamma stereotactic

radiosurgery units to deliver therapeutic doses for medical uses; or

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

43

7.48.1.2

In research involving photon-emitting remote afterloader units, teletherapy units,

or gamma stereotactic radiosurgery units in accordance with an active Investigational

Device Exemption (IDE) application accepted by the U.S. Food and Drug Administration

provided the requirements of 7.14.1 are met.

7.48.2 A licensee must use photon-emitting remote afterloader units, teletherapy units, or gamma

stereotactic radiosurgery units:

7.48.2.1

Approved in the Sealed Source and Device Registry to deliver a therapeutic dose

for medical use. These devices may be used for therapeutic medical treatments that are

not explicitly provided for in the Sealed Source and Device Registry, but must be used in

accordance with radiation safety conditions and limitations described in the Sealed

Source and Device Registry; or

7.48.2.2

In research in accordance with an active Investigational Device Exemption (IDE)

application accepted by the FDA provided the requirements of 7.14.1 are met.

7.48.3 Training For Use of a Remote Afterloader Unit, Teletherapy Unit, or Gamma Stereotactic

Radiosurgery Unit.

The licensee shall require an authorized user under 7.48 to meet the requirements of Appendix

7M.

7.49

Installation, maintenance, adjustment, and repair.

7.49.1 Only a person specifically licensed by the Department, an Agreement State, or the NRC shall

install, maintain, adjust, or repair a remote afterloader unit, teletherapy unit, or gamma

stereotactic radiosurgery unit that involves work on the source(s) shielding, the source(s) driving

unit, or other electronic or mechanical component that could expose the source(s), reduce the

shielding around the source(s), or compromise the radiation safety of the unit or the source(s).

7.49.2 Except for low dose-rate remote afterloader units, only a person specifically licensed by the

Department, an Agreement State, or the NRC shall install, replace, relocate, or remove a sealed

source or source contained in other remote afterloader units, teletherapy units, or gamma

stereotactic radiosurgery units.

7.49.3 For a low dose-rate remote afterloader unit, only a person specifically licensed by the

Department, an Agreement State, or the NRC, or an authorized medical physicist shall install,

replace, relocate, or remove a sealed source(s) contained in the unit.

7.49.4 A licensee shall retain a record of the installation, maintenance, adjustment and repair of remote

afterloader units, teletherapy units, and gamma stereotactic radiosurgery units for 3 years. For

each installation, maintenance, adjustment and repair, the record must include the date,

description of the service, and name(s) of the individual(s) who performed the work.

7.50

Surveys of patients and human research subjects treated with a remote afterloader.

7.50.1 Before releasing a patient or a human research subject from licensee control, a licensee shall

make a survey of the patient or the human research subject and the remote afterloader unit with a

portable radiation detection survey instrument to confirm that the source(s) has been removed

from the patient or human research subject and returned to the safe shielded position.

7.50.2 A licensee shall maintain a record of patient surveys which demonstrate compliance with 7.50.1

for 3 years. Each record shall include the date and results of the survey, the survey instrument

used, and the name of the individual who made the survey.

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

44

7.51

Safety procedures and instructions for remote afterloader units, teletherapy units, or

gamma stereotactic radiosurgery units.

7.51.1 A licensee shall:

7.51.1.1

Secure the unit, the console, the console keys, and the treatment room when not

in use or unattended;

7.51.1.2

Permit only individuals approved by the authorized user, RSO, or authorized

medical physicist to be present in the treatment room during treatment with the source(s);

7.51.1.3

Prevent dual operation of more than one radiation producing device in a

treatment room, if applicable; and

7.51.1.4

Develop, implement, and maintain written procedures for responding to an

abnormal situation when the operator is unable to place the source(s) in the shielded

position, or remove the patient or human research subject from the radiation field with

controls from outside the treatment room. These procedures must include:

(1)

Instructions for responding to equipment failures and the names of the individuals

responsible for implementing corrective actions;

(2)

The process for restricting access to and posting of the treatment area to

minimize the risk of inadvertent exposure; and

(3)

The names and telephone numbers of the authorized users, the authorized

medical physicist, and the RSO to be contacted if the unit or console operates

abnormally.

7.51.2 A copy of the procedures required by 7.51.1.4 must be physically located at the unit console.

7.51.3 A licensee shall post instructions at the unit console to inform the operator of:

7.51.3.1

The location of the procedures required by 7.51.1.4; and

7.51.3.2

The names and telephone numbers of the authorized users, the authorized

medical physicist, and the Radiation Safety Officer to be contacted if the unit or console

operates abnormally.

7.51.4 Operational and safety training.

7.51.4.1

Prior to the first use for patient treatment of a new unit or an existing unit with a

manufacturer upgrade that affects the operation and safety of the unit, a licensee shall

ensure that vendor operational and safety training is provided to all individuals who will

operate the unit. The vendor operational and safety training must be provided by the

device manufacturer or by an individual certified by the device manufacturer to provide

the operational and safety training.

7.51.4.2

A licensee shall provide operational and safety instructions, initially and at least

annually, to all individuals who operate the unit at the facility, as appropriate to the

individual's assigned duties. The instructions shall include instruction in:

(1)

The procedures identified in 7.51.1.4; and

(2)

The operating procedures for the unit.

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

45

7.51.5 A licensee shall ensure that operators, authorized medical physicists, and authorized users

participate in drills of the emergency procedures, initially and at least annually.

7.51.6 A licensee shall retain a record of individuals receiving instruction required by 7.51.4 in

accordance with the following:

(1)

A licensee shall maintain a record of the operational and safety instructions

required by 7.51.4 for 3 years. The record must include a list of the topics

covered, the date of the instruction, the name(s) of the attendee(s), and the

name(s) of the individual(s) who provided the instruction.

7.51.7 A licensee shall retain a copy of the procedures required by 7.51.1.4 and 7.51.4.2(2) until the

licensee no longer possesses the remote afterloader, teletherapy unit, or gamma stereotactic

radiosurgery unit.

7.52

Safety precautions for remote afterloader units, teletherapy units, and gamma stereotactic

radiosurgery units.

7.52.1 A licensee shall control access to the treatment room by a door at each entrance.

7.52.2 A licensee shall equip each entrance to the treatment room with an electrical interlock system that

will:

7.52.2.1

Prevent the operator from initiating the treatment cycle unless each treatment

room entrance door is closed;

7.52.2.2

Cause the source(s) to be shielded when an entrance door is opened; and

7.52.2.3

Prevent the source(s) from being exposed following an interlock interruption until

all treatment room entrance doors are closed and the source(s)’ on/off control is reset at

the console.

7.52.3 A licensee shall require any individual entering the treatment room to assure, through the use of

appropriate radiation monitors, that radiation levels have returned to ambient levels.

7.52.4 Except for low-dose remote afterloader units, a licensee shall construct or equip each treatment

room with viewing and intercom systems to permit continuous observation of the patient or the

human research subject from the treatment console during irradiation.

7.52.5 For licensed activities where sources are placed within the patient's or human research subject's

body, a licensee shall only conduct treatments which allow for expeditious removal of a

decoupled or jammed source.

7.52.6 In addition to the requirements specified in 7.52.1 through 7.52.5, a licensee shall:

7.52.6.1

For low dose-rate, medium dose-rate, and pulsed dose-rate remote afterloader

units, require:

(1)

An authorized medical physicist and either an authorized user or a physician,

under the supervision of an authorized user, who has been trained in the

operation and emergency response for the unit, to be physically present during

the initiation of all patient treatments involving the unit; and

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

46

(2)

An authorized medical physicist and either an authorized user or an individual,

under the supervision of an authorized user, who has been trained to remove the

source applicator(s) in the event of an emergency involving the unit, to be

immediately available during continuation of all patient treatments involving the

unit.

7.52.6.2

For high dose-rate remote afterloader units, require:

(1)

An authorized user and an authorized medical physicist to be physically present

during the initiation of all patient treatments involving the unit; and

(2)

An authorized medical physicist and either an authorized user or a physician,

under the supervision of an authorized user, who has been trained in the

operation and emergency response for the unit, to be physically present during

continuation of all patient treatments involving the unit.

7.52.6.3

For gamma stereotactic radiosurgery units, require an authorized user and an

authorized medical physicist to be physically present throughout all patient treatments

involving the unit.

7.52.6.4

If a patient or research subject suffers a medical emergency during radiation

therapy:

(1)

Cease the therapy immediately;

(2)

Remove the source(s); and

(3)

Provide appropriate care to the patient or research subject.

7.52.6.5

If the patient expires during treatment, remove the source(s) before further

actions are taken.

7.52.6.6

Notify the RSO, or his or her designee, and an authorized user as soon as

possible, if the patient or human research subject has a medical emergency and,

immediately, if the patient dies.

7.52.7 A licensee shall have applicable emergency response equipment available near each treatment

room to respond to a source:

7.52.7.1

Remaining in the unshielded position; or

7.52.7.2

Lodged within the patient following completion of the treatment.

7.53

Dosimetry equipment.

7.53.1 Except for low dose-rate remote afterloader sources where the source output or activity is

determined by the manufacturer, a licensee shall have a calibrated dosimetry system available for

use. To satisfy this requirement, one of the following two conditions must be met:

7.53.1.1

The system must have been calibrated using a system or source traceable to the

National Institute of Standards and Technology and published protocols accepted by

nationally recognized bodies, or by a calibration laboratory accredited by the American

Association of Physicists in Medicine. The calibration shall have been performed within

the previous 2 years and after any servicing that may have affected system calibration; or

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

47

7.53.1.2

The system must have been calibrated within the previous 4 years; 18 to 30

months after that calibration, the system shall have been intercompared with another

dosimetry system that was calibrated within the past 24 months by the National Institute

of Standards and Technology or by a calibration laboratory accredited by the American

Association of Physicists in Medicine. The results of the intercomparison must have

indicated that the calibration factor of the licensee's system had not changed by more

than 2 percent. The licensee shall not use the intercomparison result to change the

calibration factor. When intercomparing dosimetry systems to be used for calibrating

sealed sources for therapeutic units, the licensee shall use a comparable unit with beam

attenuators or collimators, as applicable, and sources of the same radionuclide as the

source used at the licensee's facility.

7.53.2 The licensee shall have available for use a dosimetry system for spot-check output

measurements. To meet this requirement, the system may be compared with a system that has

been calibrated in accordance with 7.53.1. This comparison shall have been performed within the

previous year and after each servicing that may have affected system calibration. The spot-check

system may be the same system used to meet the requirement in 7.53.1.

7.53.3 The licensee shall retain a record of each calibration, intercomparison, and comparison for the

duration of the license. For each calibration, intercomparison, or comparison, the record must

include:

7.53.3.1

The date;

7.53.3.2

The manufacturer’s name, the model numbers and serial numbers of the

instruments that were calibrated, intercompared, or compared as required by 7.53.1 and

7.53.2;

7.53.3.3

The correction factor that was determined from the calibration or comparison or

the apparent correction factor that was determined from an intercomparison;

7.53.3.4

The names of the individuals who performed the calibration, intercomparison, or

comparison.

7.54

Full calibration measurements on teletherapy units.

7.54.1 A licensee authorized to use a teletherapy unit for medical use shall perform full calibration

measurements on each teletherapy unit:

7.54.1.1

Before the first medical use of the unit;

7.54.1.2

Before medical use under the following conditions:

(1)

Whenever spot-check measurements indicate that the output differs by more

than 5 percent from the output obtained at the last full calibration corrected

mathematically for radioactive decay;

(2)

Following replacement of the source or following reinstallation of the teletherapy

unit in a new location; and

(3)

Following any repair of the teletherapy unit that includes removal of the source or

major repair of the components associated with the source exposure assembly;

and

7.54.1.3

At intervals not exceeding 1 year.

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

48

7.54.2 To satisfy the requirement of 7.54.1, full calibration measurements shall include determination of:

7.54.2.1

The output within +/- 3 percent for the range of field sizes and for the distance or

range of distances used for medical use;

7.54.2.2

The coincidence of the radiation field and the field indicated by the light beam

localizing device;

7.54.2.3

The uniformity of the radiation field and its dependence on the orientation of the

useful beam;

7.54.2.4

Timer accuracy, constancy, and linearity;

7.54.2.5

“On off” error; and

7.54.2.6

The accuracy of all distance measuring and localization devices in medical use.

7.54.3 A licensee shall use the dosimetry system described in 7.53 to measure the output for one set of

exposure conditions. The remaining radiation measurements required in 7.54.2.1 may then be

made using a dosimetry system that indicates relative dose rates.

7.54.4 A licensee shall make full calibration measurements required by 7.54.1 in accordance with

published protocols accepted by nationally recognized bodies.

7.54.5 A licensee shall correct mathematically the outputs determined in 7.54.2.1 for physical decay for

intervals not exceeding 1 month for cobalt 60, 6 months for cesium 137, or at intervals consistent

with 1 percent decay for all other nuclides.

7.54.6 Full calibration measurements required by 7.54.1 and physical decay corrections required by

7.54.5 shall be performed by the authorized medical physicist.

7.54.7 A licensee shall maintain a record of each calibration for the duration of the license. The record

shall include:

7.54.7.1

The date of the calibration;

7.54.7.2

The manufacturer's name, model number, and serial number for the teletherapy

unit, source(s), and instruments used to calibrate the teletherapy unit;

7.54.7.3

The results and assessments of the full calibrations; and

7.54.7.4

The signature of the authorized medical physicist who performed the full

calibration.

7.55

Full calibration measurements on remote afterloader units.

7.55.1 A licensee authorized to use a remote afterloader unit for medical use shall perform full

calibration measurements on each unit:

7.55.1.1

Before the first medical use of the unit;

7.55.1.2

Before medical use under the following conditions:

(1)

Following replacement of the source or following reinstallation of the unit in a new

location outside the facility; and

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

49

(2)

Following any repair of the unit that includes removal of the source or major

repair of the components associated with the source exposure assembly; and

7.55.1.3

At intervals not exceeding one (1) calendar quarter for high dose-rate, medium

dose-rate, and pulsed dose-rate remote afterloader units with sources whose half-life

exceeds 75 days; and

7.55.1.4

At intervals not exceeding 1 year for low dose-rate remote afterloader units.

7.55.2 To satisfy the requirement of 7.55.1, full calibration measurements must include, as applicable,

determination of:

7.55.2.1

The output within +/- 5 percent;

7.55.2.2

Source positioning accuracy to within +/- 1 millimeter;

7.55.2.3

Source retraction with backup battery upon power failure;

7.55.2.4

Length of the source transfer tubes;

7.55.2.5

Timer accuracy and linearity over the typical range of use;

7.55.2.6

Length of the applicators; and

7.55.2.7

Function of the source transfer tubes, applicators, and transfer tube-applicator

interfaces.

7.55.3 In addition to the requirements for full calibrations for low dose-rate remote afterloader units in

7.55.2, a licensee shall perform an autoradiograph of the source(s) to verify inventory and

source(s) arrangement at intervals not exceeding one quarter.

7.55.4 A licensee shall use the dosimetry system described in 7.53 to measure the output.

7.55.5 A licensee shall make full calibration measurements required by 7.55.1 of this section in

accordance with published protocols accepted by nationally recognized bodies.

7.55.6 For low dose-rate remote afterloader units, a licensee may use measurements provided by the

source manufacturer that are made in accordance with 7.55.1 through 7.55.5.

7.55.7 A licensee shall mathematically correct the outputs determined in 7.55.2.1 for physical decay at

intervals consistent with 1 percent physical decay.

7.55.8 Full calibration measurements required by 7.55.1 and physical decay corrections required by

7.55.7 must be performed by the authorized medical physicist.

7.55.9 A licensee shall retain a record of each calibration for the duration of the license. The record shall

include:

7.55.9.1

The date of the calibration;

7.55.9.2

The manufacturer's name, model number, and serial number for the remote

afterloader unit, source(s), and instruments used to calibrate the remote afterloader unit;

7.55.9.3

The results and assessments of the full calibrations;

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

50

7. 55.9.4

The results of the autoradiograph required for low dose-rate remote afterloader

units; and

7. 55.9.5

The signature of the authorized medical physicist who performed the full

calibration.

7.56

Full calibration measurements on gamma stereotactic radiosurgery units.

7.56.1 A licensee authorized to use a gamma stereotactic radiosurgery unit for medical use shall

perform full calibration measurements on each unit:

7.56.1.1

Before the first medical use of the unit;

7.56.1.2

Before medical use under the following conditions:

(1)

Whenever spot-check measurements indicate that the output differs by more

than 5 percent from the output obtained at the last full calibration corrected

mathematically for radioactive decay;

(2)

Following replacement of the sources or following reinstallation of the gamma

stereotactic radiosurgery unit in a new location; and

(3)

Following any repair of the gamma stereotactic radiosurgery unit that includes

removal of the sources or major repair of the components associated with the

source assembly; and

7.56.1.3

At intervals not exceeding 1 year, with the exception that relative helmet factors

need only be determined before the first medical use of a helmet and following any

damage to a helmet.

7.56.2 To satisfy the requirement of 7.56.1, full calibration measurements must include determination of:

7.56.2.1

The output within +/-3 percent;

7.56.2.2

Relative helmet factors;

7.56.2.3

Isocenter coincidence;

7.56.2.4

Timer accuracy and linearity over the range of use;

7.56.2.5

On-off error;

7.56.2.6

Trunnion centricity;

7.56.2.7

Treatment table retraction mechanism, using backup battery power or hydraulic

backups with the unit off;

7.56.2.8

Helmet microswitches;

7.56.2.9

Emergency timing circuits; and

7.56.2.10

Stereotactic frames and localizing devices (trunnions).

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

51

7.56.3 A licensee shall use the dosimetry system described in 7.53 to measure the output for one set of

exposure conditions. The remaining radiation measurements required in 7.56.2.1 may be made

using a dosimetry system that indicates relative dose rates.

7.56.4 A licensee shall make full calibration measurements required by 7.56.1 in accordance with

published protocols accepted by nationally recognized bodies.

7.56.5 A licensee shall mathematically correct the outputs determined in 7.56.2.1 at intervals not

exceeding 1 month for cobalt-60 and at intervals consistent with 1 percent physical decay for all

other radionuclides.

7.56.6 Full calibration measurements required by 7.56.1 and physical decay corrections required by

7.56.5 must be performed by the authorized medical physicist.

7.56.7 A licensee shall retain a record of each calibration for the duration of the license. The record shall

include:

7. 56.7.1

The date of the calibration;

7. 56.7.2

The manufacturer's name, model number, and serial number for the gamma

stereotactic radiosurgery unit, source(s), and instruments used to calibrate the gamma

stereotactic radiosurgery unit;

7. 56.7.3

The results and assessments of the full calibrations;

7. 56.7.4

The signature of the authorized medical physicist who performed the full

calibration.

7.57

Radiation surveys of therapeutic treatment units.

7.57.1 A licensee authorized to use radioactive material in remote afterloader units, teletherapy units,

and gamma stereotactic radiosurgery units shall possess a portable radiation detection survey

instrument capable of detecting dose rates over the range of 1 µSv (0.1 mrem) per hour to 500

µSv (50 mrem) per hour, and a portable radiation measurement survey instrument capable of

measuring dose rates over the range of 10 µSv (1 mrem) per hour to 10 mSv (1 rem) per hour.

The instruments shall be operable and calibrated in accordance with 7.17.

7.57.2 In addition to the survey requirements in Part 4 of these regulations, a person licensed pursuant

to Part 7 shall make surveys to ensure that the maximum radiation levels and average radiation

levels from the surface of the main source safe with the source(s) in the shielded position does

not exceed the levels stated in the Sealed Source and Device Registry.

7.57.3 The licensee shall make the survey required by 7.57.2 at installation of a new source and

following repairs to the source(s) shielding, the source(s) driving unit, or other electronic or

mechanical component that could expose the source, reduce the shielding around the source(s),

or compromise the radiation safety of the unit or the source(s).

Records of surveys of therapeutic treatment units

7.57.4 A licensee shall retain a record of the radiation surveys required by 7.57.2 for the duration of use

of the unit. The record must include:

7.57.4.1

The date of the measurements;

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

52

7.57.4.2

The manufacturer's name, model number and serial number of the treatment

unit, source, and instrument used to measure radiation levels;

7.57.4.3

Each dose rate measured around the source while the unit is in the off position

and the average of all measurements; and

7.57.4.4

The signature of the individual who performed the test.

7.58

Periodic spot checks for teletherapy units.

7.58.1 A licensee authorized to use teletherapy units for medical use shall perform output spot checks

on each teletherapy unit once in each calendar month that include determination of:

7.58.1.1

Timer accuracy, and timer linearity over the range of use;

7.58.1.2

“On off” error;

7.58.1.3

The coincidence of the radiation field and the field indicated by the light beam

localizing device;

7.58.1.4

The accuracy of all distance measuring and localization devices used for medical

use;

7.58.1.5

The output for one typical set of operating conditions measured with the

dosimetry system described in 7.53; and

7.58.1.6

The difference between the measurement made in 7.58.1.5 and the anticipated

output, expressed as a percentage of the anticipated output (i.e., the value obtained at

last full calibration corrected mathematically for physical decay).

7.58.2 A licensee shall perform spot checks required by 7.58.1 in accordance with procedures

established by the authorized medical physicist. That individual need not actually perform the

output spot-check measurements.

7.58.3 A licensee shall have the authorized medical physicist review the results of each spot check

within 15 days. The authorized medical physicist shall notify the licensee as soon as possible in

writing of the results of each spot check.

7.58.4 A licensee authorized to use a teletherapy unit for medical use shall perform safety spot checks

of each teletherapy facility once in each calendar month and after each source installation to

assure proper operation of:

7.58.4.1

Electrical interlocks at each teletherapy room entrance;

7.58.4.2

Electrical or mechanical stops installed for the purpose of limiting use of the

primary beam of radiation restriction of source housing angulation or elevation, carriage

or stand travel, and operation of the beam “on off” mechanism;

7.58.4.3

Source exposure indicator lights on the teletherapy unit, on the control console,

and in the facility;

7.58.4.4

Viewing and intercom systems;

7.58.4.5

Treatment room doors from inside and outside the treatment room; and

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

53

7.58.4.6

Electrically assisted treatment room doors with the teletherapy unit electrical

power turned “off”.

7.58.5 If the results of the checks required in 7.58.4 indicate the malfunction of any system, a licensee

shall lock the control console in the “off” position and not use the unit except as may be

necessary to repair, replace, or check the malfunctioning system.

7.58.6 A licensee shall maintain a record of each spot check required by 7.58.1 and 7.58.4, and a copy

of the procedures required by 7.58.2 for 3 years. The record shall include:

7.58.6.1

The date of the spot check;

7.58.6.2

The manufacturer's name, model number, and serial number for the teletherapy

unit, source, and instrument used to measure the output of the teletherapy unit;

7.58.6.3

An assessment of timer linearity and constancy;

7.58.6.4

The calculated “on off” error;

7.58.6.5

A determination of the coincidence of the radiation field and the field indicated by

the light beam localizing device

7.58.6.6

The determined accuracy of each distance measuring or localization device;

7.58.6.7

The difference between the anticipated output and the measured output;

7.58.6.8

Notations indicating the operability of each entrance door electrical interlock,

each electrical or mechanical stop, each source exposure indicator light, and the viewing

and intercom system and doors; and

7.58.6.9

The name of the individual who performed the periodic spot check and the

signature of the authorized medical physicist who reviewed the record of the spot check.

7.59

Periodic spot checks for remote afterloader units.

7.59.1 A licensee authorized to use remote afterloader units for medical use shall perform spot checks of

each remote afterloader facility and on each unit:

7.59.1.1

At the beginning of each day of use of a high dose-rate, medium dose-rate or

pulsed dose-rate remote afterloader unit;

7.59.1.2

Prior to each patient treatment with a low dose-rate remote afterloader unit; and

7.59.1.3

After each source installation.

7.59.2 The licensee shall have the authorized medical physicist establish written procedures for

performing the spot checks required in 7.59.1 The authorized medical physicist need not actually

perform the spot-check measurements.

7.59.3 A licensee shall have the authorized medical physicist review the results of each spot check

within 15 days. The authorized medical physicist shall notify the licensee as soon as possible in

writing of the results of each spot check.

7.59.4 To satisfy the requirements of 7.59.1, spot checks must, at a minimum, assure proper operation

of:

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

54

7.59.4.1

Emergency response equipment;

7.59.4.2

Viewing and intercom systems in each high dose-rate, medium dose-rate and

pulsed dose-rate remote afterloader facility;

7.59.4.3

Radiation monitors used to indicate the source position;

7.59.4.4

Electrical interlocks at each remote afterloader unit room entrance;

7.59.4.5

Source exposure indicator lights on the remote afterloader unit, on the control

console, and in the facility;

7.59.4.6

Timer accuracy;

7.59.4.7

Clock (date and time) in the unit's computer; and

7.59.4.8

Decayed source(s) activity in the unit's computer.

7.59.5 If the results of the checks required in 7.59.4 indicate the malfunction of any system, a licensee

shall lock the control console in the off position and not use the unit except as may be necessary

to repair, replace, or check the malfunctioning system.

7.59.6 A licensee shall retain a record of each check required by 7.59.4, and a copy of the procedures

required by 7.59.2 for 3 years. The record must include, as applicable:

7.59.6.1

The date of the spot check;

7.59.6.2

The manufacturer's name, model number, and serial number for the remote

afterloader unit and source;

7.59.6.3

An assessment of timer accuracy;

7.59.6.4

Notations indicating the operability of each entrance door electrical interlock,

radiation monitors, source exposure indicator lights, viewing and intercom systems, and

clock and decayed source activity in the unit's computer; and

7.59.6.5

The name of the individual who performed the periodic spot check and the

signature of the authorized medical physicist who reviewed the record of the spot check.

7.60

Additional technical requirements for mobile remote afterloader units.

7.60.1 A licensee providing mobile remote afterloader service shall:

7.60.1.1

Check survey instruments for consistent response before medical use at each

address of use or on each day of use, whichever is more frequent; and

7.60.1.2

Account for all sources before departure from a client's address of use.

7.60.2 In addition to the periodic spot checks required by 7.59, a licensee authorized to use mobile

afterloaders for medical use shall perform checks on each remote afterloader unit before use at

each address of use. At a minimum, checks must be made to verify the operation of:

7.60.2.1

Electrical interlocks on treatment area access points;

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

55

7.60.2.2

Source exposure indicator lights on the remote afterloader unit, on the control

console, and in the facility;

7.60.2.3

Viewing and intercom systems;

7.60.2.4

Applicators, source transfer tubes, and transfer tube-applicator interfaces;

7.60.2.5

Radiation monitors used to indicate room exposures;

7.60.2.6

Source positioning (accuracy); and

7.60.2.7

Radiation monitors used to indicate whether the source has returned to a safe

shielded position.

7.60.3 In addition to the requirements for checks in 7.60.2, a licensee shall ensure overall proper

operation of the remote afterloader unit by conducting a simulated cycle of treatment before use

at each address of use.

7.60.4 If the results of the checks required in 7.60.2 indicate the malfunction of any system, a licensee

shall lock the control console in the off position and not use the unit except as may be necessary

to repair, replace, or check the malfunctioning system.

7.60.5 A licensee shall retain a record of each check for mobile remote afterloader units required by

7.60.2 for 3 years. The record must include:

7.60.5.1

The date of the check;

7.60.5.2

The manufacturer's name, model number, and serial number of the remote

afterloader unit;

7.60.5.3

Notations accounting for all sources before the licensee departs from a facility;

7.60.5.4

Notations indicating the operability of each entrance door electrical interlock,

radiation monitors, source exposure indicator lights, viewing and intercom system,

applicators, source transfer tubes, and source positioning accuracy; and

7.60.5.5

The signature of the individual who performed the check.

7.61

Periodic spot checks for gamma stereotactic radiosurgery units.

7.61.1 A licensee authorized to use a gamma stereotactic radiosurgery unit for medical use shall

perform spot-checks of each gamma stereotactic radiosurgery facility and on each unit:

7.61.1.1

Monthly;

7.61.1.2

Before the first use on a given day; and

7.61.1.3

After each source installation.

7.61.2 A licensee shall:

7.61.2.1

Perform the measurements required by 7.61.1 in accordance with written

procedures established by the authorized medical physicist. That individual need not

actually perform the spot check measurements.

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

56

7.61.2.2

Have the authorized medical physicist review the results of each spot-check

within 15 days. The authorized medical physicist shall notify the licensee as soon as

possible, in writing, of the results of each spot-check.

7.61.3 To satisfy the requirements of 7.61.1 spot checks must, at a minimum:

7.61.3.1

Assure proper operation of:

(1)

Treatment table retraction mechanism, using backup battery power or hydraulic

backups with the unit off;

(2)

Helmet microswitches;

(3)

Emergency timing circuits; and

(4)

Stereotactic frames and localizing devices (trunnions).

7.61.3.2

Determine:

(1)

The output for one typical set of operating conditions measured with the

dosimetry system described in 7.53.2;

(2)

The difference between the measurement made in 7.61.3.2(1) and the

anticipated output, expressed as a percentage of the anticipated output (i.e., the

value obtained at last full calibration corrected mathematically for physical

decay);

(3)

Source output against computer calculation;

(4)

Timer accuracy and linearity over the range of use;

(5)

On-off error; and

(6)

Trunnion centricity.

7.61.4 To satisfy the requirements of 7.61.1.2 and 7.61.1.3, spot-checks must assure proper operation

of:

7.61.4.1

Electrical interlocks at each gamma stereotactic radiosurgery room entrance;

7.61.4.2

Source exposure indicator lights on the gamma stereotactic radiosurgery unit, on

the control console, and in the facility;

7.61.4.3

Viewing and intercom systems;

7.61.4.4

Timer termination;

7.61.4.5

Radiation monitors used to indicate room exposures; and

7.61.4.6

Emergency off buttons.

7.61.5 A licensee shall arrange for prompt repair of any system identified in 7.61.3 that is not operating

properly.

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

57

7.61.6 If the results of the checks required in 7.61.4 indicate the malfunction of any system, a licensee

shall lock the control console in the off position and not use the unit except as may be necessary

to repair, replace, or check the malfunctioning system.

7.61.7 A licensee shall retain a record of each spot-check for gamma stereotactic radiosurgery units

required by 7.61.3 and 7.61.4 for 3 years. The record must include:

7.61.7.1

The date of the spot check;

7.61.7.2

The manufacturer's name, model number, and serial number for the gamma

stereotactic radiosurgery unit and the instrument used to measure the output of the unit;

7.61.7.3

An assessment of timer linearity and accuracy;

7.61.7.4

The calculated on-off error;

7.61.7.5

A determination of trunnion centricity;

7.61.7.6

The difference between the anticipated output and the measured output;

7.61.7.7

An assessment of source output against computer calculations;

7.61.7.8

Notations indicating the operability of radiation monitors, helmet microswitches,

emergency timing circuits, emergency off buttons, electrical interlocks, source exposure

indicator lights, viewing and intercom systems, timer termination, treatment table

retraction mechanism, and stereotactic frames and localizing devices (trunnions); and

7.61.7.9

The name of the individual who performed the periodic spot check and the

signature of the authorized medical physicist who reviewed the record of the spot check.

7.61.8 A licensee shall retain a copy of the procedures required by 7.61.2 until the licensee no longer

possesses the gamma stereotactic radiosurgery unit.

7.62

Other medical uses of radioactive material or radiation from radioactive material.

7.62.1 A licensee may use radioactive material or a radiation source approved for medical use that is not

specifically addressed in Part 7 if:

7.62.1.1

The applicant or licensee has submitted the information required by 7.3.4.2,

7.3.4.3, and 7.3.4.4; and

7.62.1.2

The applicant or licensee has received written approval from the Department, an

Agreement State, or NRC in a license and uses the material in accordance with the

regulations and specific conditions that the Department, Agreement State, or NRC

considers necessary for the medical use of the material.

7.63

Full-inspection servicing for teletherapy and gamma stereotactic radiosurgery units

7.63.1 A licensee shall have each teletherapy unit and gamma stereotactic radiosurgery unit fully

inspected and serviced during each source replacement to assure proper functioning of the

source exposure mechanism and other safety components. The interval between each full

inspection servicing shall not exceed 5 years for each teletherapy unit and shall not exceed 7

years for each gamma stereotactic radiosurgery unit.

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

58

7.63.2 This inspection and servicing shall only be performed by persons specifically licensed to do so by

the Department, an Agreement State, or the NRC.

Records of full-inspection servicing for teletherapy and gamma stereotactic radiosurgery units.

7.63.3 A licensee shall maintain a record of the full-inspection servicing for teletherapy and gamma

stereotactic radiosurgery units required by 7.63 for the duration of the use of the unit.

7.63.4 The record required by 7.63.3 must contain:

7.63.4.1

The inspector's radioactive materials license number;

7.63.4.2

The date of inspection;

7.63.4.3

The manufacturer's name and model number and serial number of both the

treatment unit and source;

7.63.4.4

A list of components inspected and serviced, and the type of service; and

7.63.4.5

The signature of the inspector.

7.64

Therapy-related computer systems.

7.64.1 The licensee shall perform acceptance testing on the treatment planning system in accordance

with published protocols accepted by nationally recognized bodies.

7.64.2 At a minimum, the acceptance testing required by 7.64.1 shall include, as applicable, verification

of:

7.64.2.1

The source-specific input parameters required by the dose calculation algorithm;

7.64.2.2

The accuracy of dose, dwell time, and treatment time calculations at

representative points;

7.64.2.3

The accuracy of isodose plots and graphic displays; and

7.64.2.4

The accuracy of the software used to determine radioactive source positions

from radiographic images.

7.64.2.5

The accuracy of electronic transfer of the treatment delivery parameters to the

treatment delivery unit from the treatment planning system.

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

59

Section I – Recentness of training.

7.65

The training and experience specified in 7.65.1 through 7.65.6 must have been obtained

within the 7 years preceding the date of application or the individual must have had related

continuing education and experience since the required training and experience was

completed.

7.65.1 Section B, Section I, Appendix 7A, 7B, 7C, and 7P.

7.65.2 Section D, Appendix 7D, and 7E.

7.65.3 Section E, Appendix 7F, 7G, 7H and 7I.

7.65.4 Section F, Appendix 7J.

7.65.5 Section G, Appendix 7K and Appendix 7L.

7.65.6 Section H, and Appendix 7M.

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

60

PART 7, APPENDIX 7A: TRAINING FOR RADIATION SAFETY OFFICER (RSO) AND ASSOCIATE

RADIATION SAFETY OFFICER (ARSO)

Except as provided in Appendix 7P, the licensee shall require an individual fulfilling the responsibilities of

the Radiation Safety Officer (RSO) or an individual assigned duties and tasks as an Associate Radiation

Safety Officer (ARSO) as provided in 7.7 to be an individual who:

7A1

Is certified by a specialty board whose certification process has been recognized by the NRC or

an Agreement State and who meets the requirements in 7A4 of this Appendix. The names of

board certifications that have been recognized by the NRC or an Agreement State are posted on

the NRC’s Medical Uses Licensee Toolkit Web page. To have its certification process recognized,

a specialty board shall require all candidates for certification to:

7A1.1

(1)

Hold a bachelor's or graduate degree from an accredited college or university in

physical science or engineering or biological science with a minimum of 20

college credits in physical science;

(2)

Have 5 or more years of professional experience in health physics (graduate

training may be substituted for no more than 2 years of the required experience)

including at least 3 years in applied health physics;

and

(3)

Pass an examination administered by diplomates of the specialty board, which

evaluates knowledge and competence in radiation physics and instrumentation,

radiation protection, mathematics pertaining to the use and measurement of

radioactivity, radiation biology, and radiation dosimetry;

or

7A1.2

(1)

Hold a master's or doctor's degree in physics, medical physics, other physical

science, engineering, or applied mathematics from an accredited college or

university;

and

(2)

Have 2 years of full-time practical training and/or supervised experience in

medical physics:

(a)

Under the supervision of a medical physicist who is certified in medical

physics by a specialty board recognized by an Agreement State or NRC;

or

(b)

In clinical nuclear medicine facilities providing diagnostic or therapeutic

services under the direction of physicians who meet the requirements for

Authorized Users in Appendix 7P, Appendix 7E or Appendix 7F;

and

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

61

(3)

Pass an examination administered by diplomates of the specialty board, that

assesses knowledge and competence in clinical diagnostic radiological or

nuclear medicine physics and in radiation safety.

or

7A2

7A2.1 Has completed a structured educational program consisting of both:

(1)

200 hours of classroom and laboratory training in the following areas:

(a)

Radiation physics and instrumentation;

(b)

Radiation protection;

(c)

Mathematics pertaining to the use and measurement of radioactivity;

(d)

Radiation biology; and

(e)

Radiation dosimetry;

and

(2)

One year of full-time radiation safety experience, under the supervision of the

individual identified as the RSO, on a NRC or an Agreement State license or

permit issued by a NRC master material licensee that authorizes similar type(s)

of use(s) of radioactive material. An Associate Radiation Safety Officer may

provide supervision for those areas for which the Associate Radiation Safety

Officer is authorized on a NRC or an Agreement State license or permit issued

by a NRC master material licensee. The full-time radiation safety experience

must involve the following:

(a)

Shipping, receiving, and performing related radiation surveys;

(b)

Using and performing checks for proper operation of instruments used to

determine the activity of dosages, survey meters, and instruments used

to measure radionuclides;

(c)

Securing and controlling radioactive material;

(d)

Using administrative controls to avoid mistakes in the administration of

radioactive material;

(e)

Using procedures to prevent or minimize radioactive contamination and

using proper decontamination procedures;

(f)

Using emergency procedures to control radioactive material; and

(g)

Disposing of radioactive material;

and

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

62

7A2.2 This individual must obtain a written attestation, signed by a preceptor RSO or ARSO

who has experience with the radiation safety aspects of similar types of use of radioactive

material for which the individual is seeking approval as a RSO or an ARSO. The written

attestation must state that the individual has satisfactorily completed the requirements in

7A2.1 and 7A4 of Appendix 7A and is able to independently fulfill the radiation safety

related duties as a RSO or as an ARSO for a medical use license;

or

7A3

7A3.1 Is a medical physicist who has been certified by a specialty board whose certification

process has been recognized by the NRC or an Agreement State under Appendix 7B,

Section 7B1, has experience with the radiation safety aspects of similar types of use of

radioactive material for which the licensee seeks the approval of the individual as RSO or

an ARSO, and meets the requirements in 7A4.

or

7A3.2 Is an authorized user, authorized medical physicist, or authorized nuclear pharmacist

identified on a Department, NRC or an Agreement State license, a permit issued by a

NRC master material licensee, a permit issued by a NRC or an Agreement State licensee

of broad scope, or a permit issued by a NRC master material license broad scope

permittee, has experience with the radiation safety aspects of similar types of use of

radioactive material for which the licensee seeks the approval of the individual as the

RSO or ARSO, and meets the requirements in 7A4;

or

7A3.3 Has experience with the radiation safety aspects of the types of use of radioactive

material for which the individual is seeking simultaneous approval both as the Radiation

Safety Officer and the authorized user on the same new medical use permit issued by a

NRC master material licensee. The individual must also meet the requirements in 7A4.

and

7A4

Has training in the radiation safety, regulatory issues, and emergency procedures for the types of

use for which a licensee seeks approval. This training requirement may be satisfied by

completing training that is supervised by an RSO, an Associate RSO, authorized medical

physicist, authorized nuclear pharmacist, or authorized user, as appropriate, who is authorized for

the type(s) of use for which the licensee is seeking approval.

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

63

PART 7, APPENDIX 7B: TRAINING FOR AN AUTHORIZED MEDICAL PHYSICIST (AMP)

Except as provided in Appendix 7P, the licensee shall require the authorized medical physicist to be an

individual who:

7B1

Is certified by a specialty board whose certification process has been recognized by the NRC or

an Agreement State and who meets the requirements in 7B3 of this Appendix. The names of

board certifications that have been recognized by the NRC or an Agreement State are posted on

the NRC’s Medical Uses Licensee Toolkit Web page. To have its certification process recognized,

a specialty board shall require all candidates for certification to:

7B1.1 Hold a master's or doctor's degree in physics, medical physics, other physical science,

engineering, or applied mathematics from an accredited college or university;

7B1.2 Have 2 years of full-time practical training and/or supervised experience in medical

physics:

(1)

Under the supervision of a medical physicist who is certified in medical physics

by a specialty board whose certification process has been recognized under 7B1

by the NRC or an Agreement State;

or

(2)

In clinical radiation facilities providing high energy, external beam therapy

(photons and electrons with energies greater than or equal to 1 million electron

volts) and brachytherapy services under the direction of physicians who meet the

requirements in Appendix 7P, Appendix 7K or Appendix 7M;

and

7B1.3 Pass an examination administered by diplomates of the specialty board, that assesses

knowledge and competence in clinical radiation therapy, radiation safety, calibration,

quality assurance, and treatment planning for external beam therapy, brachytherapy, and

stereotactic radiosurgery;

or

7B2

7B2.1 Holds a master's or doctor's degree in physics, medical physics, other physical science,

engineering, or applied mathematics from an accredited college or university; and has

completed 1 year of full-time training in medical physics and an additional year of full-time

work experience under the supervision of an individual who meets the requirements for

an authorized medical physicist for the type(s) of use for which the individual is seeking

authorization. This training and work experience must be conducted in clinical radiation

facilities that provide high-energy, external beam therapy (photons and electrons with

energies greater than or equal to 1 million electron volts) and brachytherapy services and

must include:

(1)

Performing sealed source leak tests and inventories;

(2)

Performing decay corrections;

6 CCR 1007-1 Part 7

Hazardous Materials and Waste Management Division

64

(3)

Performing full calibration and periodic spot checks of external beam treatment

units, stereotactic radiosurgery units, and remote afterloading units as applicable;

and

(4)

Conducting radiation surveys around external beam treatment units, stereotactic

radiosurgery units, and remote afterloading units as applicable;

and

7B2.2 Has obtained written attestation that

This text is long and has been trimmed here. Open the source document for the complete record.

This is a copy of a public record, reproduced as it was published. It is not legal advice, and it may not be the version a court would rely on. Check the official source before you cite it.

A word about cookies

We need a few to keep you signed in and the library working. The rest help us see which pages people use and where they get stuck. They stay off unless you say yes.